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ABSTRACT 
The Rel!NF-xB and TGF-~/SMAD signal transduction pathways are essential for 
maintaining homeostasis, controlling cell proliferation and survival in every species studied 
and in many different cell and tissue types. Both pathways are implicated in numerous 
cancers resulting from their abnormal regulation. For instance, constitutive Re1/NF-xB 
activity leads to continous pro-survival stimulation allowing cancer cells the opportunity to 
continue growing in otherwise detrimental conditions. Also, due to its role in growth 
suppression, TGF-~-insensitivity has been reported in a majority of tumor types. Until 
recently, however, very few studies have attempted to determine whether there are 
interactions between the signaling members of each of these pathways. Therefore, this study 
was designed for this purpose. 
The tetracycline-inducible system (Tet-On) was chosen to control the expression of 
a constitutively active Re1/NF-xB member, Xrel3, in CaSki human cervical carcinoma cell 
lines. The responses to TGF -~ stimulation were measured in Xrel3-expressing and non-
expressing CaSki cells to investigate whether the presence o fXrel3 affects TGF -~ signaling. 
This thesis provides evidence that Xrel3 is able to block the TGF-~-induced growth 
inhibition, and P AI -1 and p21 induction, but not SMAD2 phosphorylation or p 15 induction 
in CaSki cervical cancer cells. A mutated form of Xrel3, mutNLS, was not able to affect 
TGF-~ responses of growth inhibition or marker induction. These results suggest that 
constitutive Rel/NF -KB activity may be responsible for the loss of sensitivity to TGF -~ and 
may provide insight for therapeutic strategies for treating tumors which display this activity. 
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CHAPTER! 
INTRODUCTION 
1.1 Intracellular Signal Transduction 
Signaling from outside the cell surface to the nucleus in response to extracellular 
stimuli is a highly complex process involving a great variety of ligands and stimuli, cell 
surface receptors, signaling molecules, as well as all of the appropriate target genes and 
proteins for each situation. Intracellular signal transduction pathways are therefore assigned 
to cascades or families of cascades based on structure, function, ligands, targets, or a 
combination of these factors. The outcome of successful signal transduction could include 
the activation or prevention of cell division, stem cell differentiation, hormone secretion, 
muscle contraction, nerve conduction, or an immune reaction. 
Due to the complexity of the signaling process, the coordination of transmitting the 
intended signal for a particular stimulus has many potential obstacles. If any of the 
components of the signaling mechanism become altered, such that they lose or gain 
responsiveness to a particular stimuli, it will often manifest consequences for the cell that 
directly result in disease conditions. The classic example is a cancer cell that is 
hyperproliferating due to constitutive activation of a particular growth-promoting signal 
pathway. In fact, many human diseases result from malfunctioning signal transduction 
pathways. For this reason, it is highly important to understand not only how each individual 
cascade functions, but also how they are able to communicate or cross-talk within the cell 
to modify and regulate the thousands of potential outcomes. 
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This thesis will focus on two important signal transduction pathways that involve the 
Rel!NF-KB family of transcriptional regulators and the transforming growth factor (TGF)-P 
superfamily of signaling molecules. Both pathways are implicated in various cancers and 
recent studies indicate interactions between them exist in order to modify and regulate the 
individual responses. A complete understanding ofboth pathways will be necessary in order 
to evaluate future therapeutic options for understanding and controlling carcinogenesis (Garg 
and Aggarwal, 2002). 
1.2 Rei/NF-KB Family of Transcriptional Regulators 
The Rel/NF-KB (nuclear factor-kappaB) family of ubiquitously expressed 
transcriptional regulators are highly conserved proteins and are activated via a well studied 
signaling pathway. They are involved in regulating immtme responses (Grilli eta/., 1993; 
Kopp and Ghosh, 1995; Ghosh eta/., 1998), apoptosis (Sonenshein, 1997), neural signaling 
(Grilli and Memo, 1999), cell growth (Foo and Nolan, 1999), cell cycle progression (Joyce 
eta/., 2001) and potential carcinogenesis (Bours eta/., 1994; Luque and Gelinas, 1997). 
1.2.1 Structure of Rei Proteins 
All Rei proteins contain theN-terminal Rei Homology Domain (RHD) that shares 
35-61% identity between family members (Baldwin, 1996). The RHD has four motifs that 
are responsible for the characteristic functions of all Rei members including DNA binding, 
dimerization, nuclear localization, and interaction with inhibitory IKB family members (Chen 
3 
and Ghosh, 1999). Rel proteins are found in vivo as homodimers or heterodimers and 
regulate transcription oftarget genes by binding 10 base pair (bp) promoter sequences called 
KB sites containing the consensus 5'-GGGGYNNCCY-3' sequence (Kunsch et al., 1992). 
The specific sequence of each KB site varies and determines the binding affmities of each Rei 
dimer thus conferring greater diversity in cellular responses (Menetski, 2000). 
1.2.2 ClasSification of Rei Family Members 
The prototype of the Rei family was identified in mature B cells as a nuclear factor 
necessary for K light chain transcription and was therefore named NF-KB (Sen and 
Baltimore, 1986a). Since the characterization ofNF-KB, several Rel family members have 
been identified and are divided into two classes (Figure 1.1 ). This dichotomy is based on the 
sequences of their variable C-terminal regions while the RHD domain is common to all Rel 
members and is found at theN-terminus. 
The Class I Rel proteins include p 105 and p 100 which are proteolytically cleaved to 
give the active forms p50 and p52 respectively, and the Drosophila homologue Relish 
(Gnosh et al., 1998). Although similar in structure and function, p105 and p100 differ in 
their regulation. The cleavage of p 105 is constitutive while the processing of p 100 is highly 
regulated (Xiao et al. , 2001). Class I Rel proteins contain approximately seven ankyrin 
repeats at the C-terminus that inhibit activation of the protein until they are cleaved at the 
protease site (Figure 1.1 ), releasing the shorter, active form. These Re1 members are 
Class I 
Examples: p50/p105, p52/p100, Relish 
Rei-homology domain (RHO) 
~ DNA Binding -+ Dimerization -+ NLS1 
Class II 
Ankyrin Repeats 
I I 
Examples: ReiA, ReiB, c-Rel, Dorsal, Xrel3 
Rei-homology domain (RHO) Transactivation Domain 
~ DNA Binding -+ Dimerization -f NLSi 
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Figure 1.1 Classification and structure ofRel/NF-KB proteins. All Rel!NF-KB members 
contain the characteristic Rei Homology Domain containing sequences necessary for DNA-
binding, interactions with IKB members, and a nuclear localization signal. Class I Rel!NF-
KB members contain several inhibitory ankyrin repeat sequences that are proteolytically 
cleaved for activation. Class II Rel!NF -KB members contain a transactivation domain in the 
C-terminus that is essential for Rel activity. 
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therefore considered inhibitory Rel proteins unless they are heterodimerized with a member 
of the activating Class II Rel proteins (Gilmore, 1999). 
Class II Rel/NF-'KB members contain at least one transactivation domain in the C-
terminus that is necessary for the activation oftarget gene expression (Schmitz et al., 1994). 
They include RelA (or p65), Re1B, c-Rel, Dorsal, v-rel, Xrel3, and the Drosophila Dif 
protein (Gnosh et al., 1998). All ofthese members are able to form homodimers (with the 
exception ofRelB) and heterodimers. The NF-'KB heterodimer is composed of one RelA 
protein and one p50 protein bound in a complex and will be described in detail later in the 
text. 
1.2.3 The Rei/NF-'KB signaling pathway 
Rel!NF-KB responds to many varied exogenous and endogenous stimuli 
(summarized in Pahl, 1999 ). NF-KB pathways can be activated by the products of infectious 
agents, such as bacterial outer surface lipopolysaccharide (LPS) (Sen and Baltimore, 1986b; 
Guha and Mackman, 2001), viral transactivating proteins such as Tax, the human T-cell 
leukemia viral protein (Leung and Nabel, 1988; J eang, 2001 ), or double-stranded viral RNA 
(Visvanathan and Goodboum, 1989; Kaufman, 1999). NF-KB can also be activated as part 
of the stress response by cell damaging agents such as ultraviolet (UV) light (Stein et al. , 
1989) orreactiveoxygenspecies, ROS (Schreck eta/., 1991; Mercurio and Manning, 1999). 
Proinflammatory cytokines such as interleukin-1 (IL-l), IL-2, and tumor necrosis factor-a 
(TNF-a) are potent inducers ofRel transactivationactivity (Osbom et al., 1989; Hazan eta!., 
6 
1990; Israel eta/., 1989). Some anti-cancer therapeutic drugs are known activators of 
Rel!NF-KB members including cisplatin (Nie eta/., 1998) and tamoxifen (Ferlini et al., 
1999). Follicle stimulating hormone (FSH), insulin, and TGF-cx will also activate NF-KB 
(Delfino and Walker, 1998; Bertrand et al., 1995; Lee et al., 1995). The combined results 
highlight the ubiquitous nature of ReliNF -KB signaling and the universal significance of 
Re1JNF-KB in cell growth, function, and homeostasis. 
NF-KB is the most extensively studied Rel member and whose pathway is best known 
(Figure 1.2). NF -KB is normally found sequestered in an inactive state within the cytoplasm, 
bound to a member of the IKB family. This family contains seven mammalian members, 
lKBcx, lKBP, lKBy, IKB€, Bcl-3, and the plOO and p105 Rei precursors (Ghosh eta/., 1998). 
IKB proteins contain multiple ankyrin repeats which interact with Rei proteins. The IKB 
ankyrin repeats each form two helices followed by a hairpin loop (Huxford et al., 1998; 
Jacobs and Harrison, 1998) that stack on each other to form finger-like extensions (Ghosh 
and Karin, 2002). These extensions interact with the RHD to inhibit Rel!NF-KB activity. 
The stimulation of NF-KB is initiated when an extracellular signal leads to the 
activation of the IKB kinase (IKK) complex (Figure 1.2). This complex is estimated to be 
greater than 700 kDa and contains IKKcx, IKKP, and NEMO/IKK y along with other 
suspected components such as Cdc37 and Hsp90 (Chen eta/., 2002). IKK phosphorylates 
IKB proteins on serine residues at theN-terminus, an event that targets lKB for ubiquitination 
at lysine residues by a specific ubiquitin ligase in the Skp-1/Cul/F box (SCF) family (Ben-
7 
SIGNAL 
(Ub)n 
NF-KB 
Nucleus Cytoplasm 
Figure 1.2 Intracellular signal transduction via NF-KB. Once stimulated, the IKB kinase 
complex (IKK) phosphorylates its downstream target, IKB that normally sequesters NF-KB 
in the cytoplasm. Following phosphorylation, IKB is targeted for polyubiquitination and 
subsequent degradation by the 26S proteoasome. 
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Neriah, 2002). Polyubiquitination of lKB leads to its rapid degradation by the 26S 
proteasome (Karin and Ben-N eriah, 2000), unmasking the NF-KB nuclear localization signal 
(NLS). NF-KB is then able to translocate to the nucleus where it can bind KB promoter sites 
and activate target genes (Figure 1.2). The kinetics of this process have been studied and it 
has been found to take approximately 16 minutes for nuclear accumulation ofRelA (and 
therefore p50) following TNF-a stimulation (Nelson et al. , 2002). 
While this scenario appears to be complete, there are many details that are unknown. 
Many regulatory mechanisms have been suggested at almost every stage of the ReliNF-KB 
pathway that modify the signal to produce the ligand-specific response. For instance, NF-
KB:IKB complexes have been shown to continuously shuttle in and out of the nucleus, 
controlled by the balancing of NLS and nuclear export signals (NBS) in each molecule 
(Johnson et al., 1999; Rodriguez et al., 1999; Huang et al. , 2000; Tam et al., 2000). The 
significance of this nuclear shuttling ofNF -KB :lKB complexes is not clear (Ghosh and Karin, 
2002). Second, Rel proteins themselves can be posttranslationally modified. Most Rel 
proteins contain a consensus sequence for protein kinase A (PKA) phosphorylation 
(Naumann and Scheidereit, 1994; Neumann et al, 1995). This phosphorylation enhances 
dimer-DNA binding (Neumann et al., 1995) and enables interactions with CBP/p300 
transcriptional coactivators (Zhong et al., 2002). Many recent studies indicate that Rel 
phosphorylation is a regulator ofRel activity; however its importance is still unclear (Martin 
et al., 2000; Wang et al., 2000; Martinet al. , 2001). 
More evidence is accumulating that Rel/NF -KB activation may alternatively involve 
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an IKE-independent mechanism (Lienhard Schmitz et al., 2001). This model involves the 
phosphorylation of NF-KB at various residues by kinases other than IKK, that leads to a 
conformational change ofNF-KB, stimulating nuclear accumulation and interactions ofNF-
KB with co-activators and co-repressors. Rel!NF-KB proteins have all been shown to be 
activated by casein kinase II (Wang et al., 2000), protein kinase C( and RasP21 (Anrather et 
al., 1999), mitogen- and stress-activated protein kinase 1 (MSK -1) (Krause et al., 1998), p38 
MAPK (Carteret al., 1999; Carter and Hunninghake, 2000), Akt or protein kinase B (Ozes 
et al., 1999), and glycogen synthase kinase-3~ (Hoeflich et al., 2000). Therefore, much 
more research is needed in these areas to determine how these factors all act to regulate 
Rel!NF-KB pathways. 
1.2.4 Rei-DNA binding 
Every Rel dimer has its characteristic DNA binding site specificity and affinity (Chen 
and Ghosh, 1999) resulting in variable transactivation potential depending on the Rel 
member, cell type, growth conditions, and differentiation stage (Kang et al., 1992; Plaksin 
et al., 1993; Brown et al., 1994; Hansen et al., 1994a; Hansen et al., 1994b ). Three-
dimensional structures of many Rei members binding to their KB sites have been analyzed 
(Ghoshetal. , 1995;Miilleretal., 1995;Crameretal., 1997;Cheneta/., 1998). Reldimers 
straddle DNA, giving rise to a unique tertiary structure that has not been found in other 
transcription factors. Contained within the RHD, are two N-terminal ~ sheet folds which 
bind DNA in a base-specific and a backbone-nonspecific fashion (Coleman et al., 1993; 
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Toledano et al., 1993). Extending from these folds are ten flexible loops that mediate direct 
DNA contacts with KB sequences. These contacts are contained within two subsites ofKB 
sequences that are pseudo symmetric (Chen and Ghosh, 1999) and are combinations ofDNA 
nucleotide base-specific contacts within the major groove, (for example, arginine residues 
contact conserved guanines), hydrogen bonds (for example, glutamate residues bind 
cytosines), and van der Waals contacts (for example, positively-charged arginine interacts 
with pyrimidine bases) (Chen and Ghosh, 1999). 
Specific DNA sequences are known to preferentially bind to celiain dimers and also 
to be present in various complexes containing unique teliiary structures (Menetski, 2000). 
Due to the many existing forms of Rei dimers and the various sequences found in KB 
promoter sites, it is not surprising that Rei proteins are involved in so many cellular 
functions. 
1.3 The Transforming Growth Factor ~ (TGF -~) Superfamily and Signal 
Transduction 
1.3.1 The TGF-~ Superfamily 
The TGF -P signal transduction pathway is another ubiquitous signaling cascade that 
has been studied extensively due to its roles in many cellular processes. This signaling 
cascade is activated by a superfamily of structurally related and highly conserved growth 
factors whose prototype is TGF -P 1 (reviewed in Massague, 1998; Massague eta!., 2000). 
These growth factors and their internal signaling mechanisms help regulate cell proliferation 
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and differentiation (Moses and SeiTa, 1996; Yue and Mulder, 2001; ten Dijke et al., 2002), 
embryonic development (Wall and Hogan, 1994; Whitman, 2001), cell cycle regulation 
(Alexandrow and Moses, 1995; Hocevar and Howe, 1998), cell motility (Nakata et al., 
2002), wound healing and maintenance ofthe extracellular matrix (ECM) (Verrecchia and 
Mauviel, 2002), aging (Blumenfeld et al., 2002), and cellular adhesion (Dunker and 
Krieglstein, 2000). 
The TGF-~ superfamily contains 28 known and predicted members (Venter et al., 
2001) and includes the activins, bone morphogenetic proteins, vegetal factors (V g), the TGF-
~ subfamily members, and many other more distant members. A list of the common TGF -~ 
family members and their known functions are listed in Table 1.1. The active form ofTGF -~ 
proteins are dimeric complexes, usually bound by a disulfide bond or hydrophobic 
interactions (Sun and Davies, 1995); however it does exist in a latent form as well 
(Lawrence, 2001). Loss ofTGF-~ signaling has been linked to many disorders including 
many cancers (Teicher, 2001; Wakefield and Roberts, 2002). Due to the physiological and 
pathological roles of the TGF-~ superfamily, it is key to understand TGF-~ signaling, its 
regulation, and its effects on target genes in order to elucidate where errors can possibly 
occur in associated disorders. 
1.3.2 TGF-(3 Receptor Family 
Signaling ofTGF-~ is initiated by ligand binding to its appropriate TGF-~ receptor 
Table 1.1. The Transforming Growth Factor P (TGF-P) 
Superfamily Divisions 
TGF -~ Subfamily 
Activin 
Activin ~A 
Activin ~B 
Activin ~C 
Activin ~E 
BMP2 
BMP2 
BMP4 
BMP3 
BMP3/osteogenin 
GDFlO 
BMP5 
Function 
Follicle-stimulating hormone 
production, erythroid cell 
differentiation, mesoderm induction 
Important roles in gastrulation, 
neurogenesis, chondrogenesis, and 
mesoderm patterning 
Endochondral bone formation; 
osteogenic differentiation; 
monocyte chemotaxis 
References 
Harland, 1994; Gaddy-Kurten et 
al., 1995 
Hogan, 1996; Mehler et al., 
1997; Harland, 1994 
Cunningham et al., 1992 
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BMP5 
BMP6Ngr1 
BMP7/0P1 
BMP8/0P2 
Necessary for the development of 
virtually all organs especially 
during neurogenesis 
Hogan, 1996; Mehler et al., 1997 
GDF5 
GDF5/CDMP1 
GDF6/CDMP2 
GDF7 
TGF-P 
TGF-Pl 
TGF-~2 
TGF-~3 
Chondrogenesis in embryonic 
development 
Epithelial cell cycle arrest; wound 
healing; immunosuppression; 
extracellular matrix production 
Hogan, 1996; Kingsley, 1994 
Massague, 1990; Roberts and 
Sporn, 1993; Alexandrow and 
Moses, 1995 
Table 1.1. The Transforming Growth Factor P (TGF-P) 
Superfamily (continued) 
TGF-P Subfamily 
Vgl 
GDFl/Vgl 
GDF3/Vgr2 
Intermediate Members 
Nodal/Xnr 
Dorsalin 
GDF8 
GDF9 
Distant Members 
Function 
Axial mesoderm induction 
Mesoderm induction; left-right 
asymetry; neural tube cell 
differentiation; inhibition of 
skeletal muscle growth 
References 
Kingsley, 1994 
Basler, et al., 1993; Beddington, 
1996;Hogan, 1996;McPherron 
et al., 1997 
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MIS/AMH 
Inhibin a 
Mullerian duct regression; 
inhibition of activin; dopaminergic 
neuron survival; kidney formation 
and development 
Josso et al., 1993; Gaddy-Kurten 
et al., 1995; Massague, 1996 
GDNF 
BMP, bone morphogenetic protein. CDMP, cartilage-derived morphogenetic protein. GDF, growth and 
differentiation factor. GDNF, glial cell-derived nerotrophic factor. MIS/AMH, Mullerian inhibiting 
substance/anti-Mullerian hormone. OP, osteogenic protein. TGF, transforming growth factor. Vg, 
vegetal. Xnr, Xenopus nodal-related protein. (Adapted from Massague, 1998). 
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(T~R) family of serine-threonine kinases. This family of receptors is divided into two 
groups based on structure and function (see Table 1.2). Type I receptors are 
unphosphorylated homodimers prior to ligand binding whereas type II receptors have a 
constitutive kinase activity that autophosphorylates on serine residues (Derynck and Feng, 
1997; Dennler eta/., 2002). All TGF-~ type I receptors contain three essential domains, the 
extracellular domain, the GS domain, and the kinase domain (Massague, 1998; Dennler et 
a/., 2002). The extracellular domains ofboth type I and II receptors have approximately 150 
amino acids and are N-glycosylated (Wells eta/., 1997). The T~R extracellular domain also 
contains a cluster of cysteines adjacent to the transmembrane sequence and up to ten or more 
other cysteine residues scattered about the extracellular domain (Wrana et al., 1994). The 
arrangement of these cysteine residues influences the overall three-dimensional stmcture of 
each receptor via the intramolecular disulfide bonds formed between them (Fischer et al., 
1999). A feature within the intracellular domain common to only T~R-lis is the constitutive 
phosphorylation of a serine residue in the non-ligand bound state (Luo and Lodish, 1997). 
Type I receptors, T~R-Is, contain a glycine-serine (GS) domain with the highly 
conserved TTSGSGSG sequence adjacent to the protein kinase domain (Wrana et al., 1994). 
Activation of type I receptors by ligand binding involves the phosphorylation of this 
sequence at the serine and threonine residues (Souchelnytskyi eta/., 1996). Due to its role 
in regulating TGF-~-induced cell responses, when the GS domain is mutated it leads to 
constitutive activity that occurs mostly on a threonine or glutamine residue located 
immediately adjacent to the kinase domain (Wieser eta/. , 1995). 
Table 1.2. Mammalian and Xenopus TGF -P Type I 
and Type II Receptor Families 
TjJRI 
ActR-1 (ALIQ) 
ActR-1B (ALK4) 
ALK1 
ALK7 
ALK8 
BMPR-1A (ALK3) 
BMPR-lB (ALK6) 
Tf3R-1 (ALK5) 
XTrR-II 
TjJRII 
ActRII 
ActR-IIB 
AMHR 
BMPR-II 
TPR-11 
References 
Attisano et al., 1993; Yamashita et al., 1995 
Carcamo et al., 1994 
Attisano et al., 1993 
Tsuchida eta/., 1996; Ryden et al., 1996 
de Caestecker eta/., 2002 
Yamashita et al., 1995 
Koenig eta!., 1994 
Yamashita et al., 1994 
Mahony and Grudon, 1995 
Mathews and Vale, 1991; Attisano eta/., 1992; 
Mathews et al. , 1992 
Baarens eta/., 1994; di Clemente et al., 1994 
Liu et al., 1995; Nohno eta/., 1995; Rosenzweig et al., 1995 
Lin et al., 1992 
ActR, activin receptor. ALK, activin receptor-like kinase. AMHR, anti-Mullerian hormone receptor. 
BMPR, bone morphogenetic protein receptor. TPR, transforming growth factor P receptor. XTrR, 
Xenopus transforming growth factor P-related receptor. Adapted from Massague, 1998. 
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The functional intracellular serine/threonine kinase domain is common in both TGF-
P type I and type ll receptors (Mathews and Vale, 1991; Frazen eta!., 1993). TPR-I 
substrates are the serine residues of Sma- and Mad-related proteins (SMADs) which function 
to transmit TGF-P and activin signals to the nucleus (SMADs 2 and 3) (Macias-Silva et at. , . 
1996) or BMP signals (SMADs 1, 3, and 5) (Kretzschmar et a!., 1997). The TPR-II 
autophosphorylate (Mathews and Vale, 1993) and TPR-I on serine and threonine residues 
(Wrana et al., 1994; Wrana, 1998). Unlike the tyrosine kinase receptor family ( eg: fibroblast 
growth factor, FGF, receptors) which have a critical C-terminal region necessary for signal 
transduction (McKeehan et at., 1998; Powers et al., 2000), TGF-P receptors do not contain 
functionally important C-terminal regions (Wieser et al., 1993). TPR-I has negligible C-
terminal region beyond the kinase domain while TPR-II has a short extension that does not 
appear to be important for signaling. Only BMPR-II contains a C-terminal region, but it has 
no known function (Kawabata et al., 1995; Nohno eta!., 1995). 
1.3.3 SMAD Family of Signal Transducers 
The intracellular communication ofTGF -P signals is dependent on the Sma and Mad 
(SMAD) related proteins. The SMADs comprise a family whose members are ubiquitously 
expressed throughout development and are found in all adult tissues (Flanders et al., 2001; 
Luuko et al. , 2001). They were first identified in Drosophila (Raftery et al., 1995; Sekelsky 
eta!., 1995) and C. elegans (Savage et at., 1996) and later termed SMADs when eight 
members were identified in vertebrates (Riggins eta/., 1996). 
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SMAD proteins have two homologous domains, the N-terminal Mad-homology 1 
(MH1) domain and the C-terminal Mad-homology 2 (MH2) domain connected by a proline-
rich linker region (Yue and Mulder, 2001). In addition to these characteristic conserved 
motifs, SMAD proteins are functionally divided into three groups. In the first group, the 
receptor-activated SMADs (R-SMADs) are phosphorylated by type I receptors and are 
comprised of SMADs 1,2,3,5, and 8. The second group are the common-partner SMADs 
(co-SMADs), that dimerize with activated R-SMADs whose only mammalian homologue 
is SMAD4. The third group are the inhibitory SMADs (I-SMADs), which include the 
mammalian SMADs 6 and 7 (Moustak:as et al., 2001). 
1.3.4 SMAD Activation and Signal Transduction 
TGF -P signal transduction is activated by the formation of a heterotetrameric receptor 
complex of two type I receptors (TPR-I) and two type II receptors (TPR-II) bound by the 
dimeric TGF-P superfamily ligand (Massague, 1998; Figure 1.3). This complex can be 
formed in one of two ways. First, TGF-P and activin ligands bind to TPR-II which then 
recruits TPR-I in a sequential manner (Attisano et al., 1993; Ebner et al., 1993). 
Alternatively, BMP ligands bind both types of receptors cooperatively with high affinity (Liu 
et al., 1995; Nohno et al., 1995). In the latter situation, both types of receptors have a low 
ligand affinity individually, but when present together, their affinities increase. 
Following the formation of the heterotetrameric TGF -P receptor complex, the two 
type I receptors phosphorylate two C-terminal serine residues ofthe R -SMADs, SMAD2 and 
TGF-~L] 
~ 
00 
R..SMAD 
CX) 
--~) Co-SMAD 
Cytoplasm 
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Figure 1.3 Transforming growth factor p signals through the SMAD proteins. Upon 
ligand binding, TPR-ll phosphorylates TPR-I which then activates a R-SMAD by 
phosphorylation. The activated R-SMAD recruits a co-SMAD and the dimer translocates 
to the nucleus to regulate transcription of various target genes. 
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SMAD3. Activated R-SMADs then complex with the co-SMAD, SMAD4. The 
stoichiometry of this complex has been debated in the literature and has been reported to be 
heterodimeric (Wu et al., 2001 ), heterotrimeric (Chacko et al., 2001 ), and heterohexameric 
(Shi et al., 1997). It is likely to be dependent upon many factors including cell conditions, 
specific-ligand binding, or availability of each R-SMAD and co-S MAD. 
Activation of SMADs alter their conformation that lead to their accumulation in the 
nucleus due to exposure of a NLS-like sequences in the N-terminus (Pierreux et al., 2000; 
Watanabe et al., 2000). Nuclear SMAD complexes can bind directly to specific DNA 
sequences called SMAD binding elements (5'AGAC-3') or indirectly via associations with 
other transcriptional factors (Heldin et al., 1997), such as FAST-1 (Figure 1.3). 
1.3.5 Regulation ofTGF-~/SMAD Signaling 
As with the Rel!NF-KB signal transduction pathway, much more data has been 
accumulating recently regarding the regulation ofSMAD-mediated activation and repression. 
Firstly, it is now known that the presentation of ligand to the receptor can be controlled by 
TGF-~-binding proteins such as betaglycan (L6pez-Casillas et al. , 1994) and endoglin 
(Barbara et al., 1999; Ma et al., 2000). The data is controversial in that betaglycan has been 
shown to repress TGF-~1/TPR-II formation but enhances TGF-P21TPR-II binding. It is 
assumed that this ability to repress TGF-P l!T~R-II formation is regulated by the 
glycosaminoglycan modifications (Eickelberg et al., 2002). Secondly, many of the SMADs 
require C-terminal phosphorylation of the MH2 domain in order to bind SMAD binding 
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elements (Dennler eta/., 1998; Johnson eta/., 1998; Shi eta/., 1998). Thirdly, R-SMADs 
are able to recruit co-activators p300 and CBP by their MH2 domains (Feng eta/., 1998; 
Nishihara eta/., 1998; Pearson eta/., 1999). Fourthly, SMAD nuclear interacting protein 
1 (SNIP1) interacts with SMAD4 preventing associations with CBP/p300 and repressing 
TGF-P signaling (Kim et a/., 2000). For a complete summary of all TGF-P/SMAD 
regulators, co-activators, repressors, and co-repressors, see ten Dijke eta/. (2002). 
Because of the importance of TGF-P and the complexity of regulating TGF-P 
signaling, it is not surprising to find examples of mutations that lead to a diseased state in its 
pathway. TGF-P-Iigand mutations are responsible for hereditary chondrodysplasia and 
persistent Mullerian duct syndrome (Attisano and Wrana, 2002). Also, TGF-P is a growth 
suppressor and therefore mutations have been found in many cancers which become resistant 
to its growth inhibitory effects (Massague eta/., 2000; de Caestecker eta/., 2000; Teicher, 
2001). Clearly, there is a need to expand our knowledge for how this pathway is regulated 
in order to provide a basis for therapeutic advances. 
1.4 Experimental Strategies for Regulating Gene Expression in 
Mammalian Cell Lines 
The study of gene expression within a cell can be problematic because the effects are 
often cell-specific or are dependent on the cell culture conditions. To fully understand the 
impact of a gene product on a given cell requires comparison of cell behavior after 
modulating the level of that gene product while maintaining all other variables. The most 
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common technique for establishing these conditions is to remove or "knock-out" the gene 
of interest using homologous recombination, site-specific mutagenesis, neutralizing 
antibodies or more recently, anti-sense, and interference RNA technology. These methods 
are particularly useful in determining the necessity ofthe gene product of interest for certain 
functions such as normal growth patterns or signal transduction. However, it is often 
desirable to determine the effects of a gene product in a particular cell type. Stable 
transfections of cells with genes has been one very useful mechanism; however controlling 
gene expression has been difficult. The classical procedure involves inserting DNA 
encoding the gene of interest into the cell genome under the control of a constitutive 
promoter such as the cytomegalovirus promoter (CMV). The researcher has no control over 
the degree of transcription or the timing of transcription that may contribute to the results of 
the experiment. Also, the effects of unknown changes occurring during transfecting, 
selecting and growing clones often generate uncertainties in cell characteristics that cannot 
be controlled. 
1.4.1 Inducible Gene Expression 
The induction of gene expression by an effector is not a novel idea. Many systems 
have been designed and employed that use inducible promoters from heat shock proteins, 
metal ion activators, and steroid hormone induction (reviewed in Yarranton, 1992; Hirt et 
al., 1994; Saez et al. , 1997; Rossi and Blau, 1998; Walker et al., 1999). One of the more 
extensively studied systems involved using the E. coli lac operon model. The lac operon has 
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a tightly controlled operator (/aeO)-repressor (ZaeR) complex which prevents transcription 
of the lactose metabolism genes by blocking the binding of RNA polymerase. In the 
presence oflactose or its synthetic homologue isopropyl-~-D-thiogalactopyranoside (IPTG), 
the ZaeR is sequestered from lacO by binding to IPTG allowing RNA polymerase binding 
and induction ofthe lac operon genes. In eukaryotic cells, however, this system has not been 
as fruitful as anticipated. Several problems arose when attempting to develop stable lac-
containing cell lines (Gossen et al., 1993). First, induction rarely produced levels greater 
than 60-fold. The chromosomal position of the tacO sequence can affect the properties of 
the promoter and the induction rates. Second, it was found that elongation factor SII can 
bypass the lacO-R complex and initiate transcription. Third, studies involving kinetics were 
not always possible in eukaryotic cells due to the slow action of IPTG in removing ZaeR 
from its operator sequence. For these reasons, the lac operon system is not as useful as 
another inducible gene system, the tetracycline-resistance operon found on the prokaryotic 
TnlO transposon (Foster et al., 1981). 
1.4.2 Tetracycline-Inducible Gene Systems 
Tetracycline-inducible conditional gene expression systems have been developed, 
based on the E. coli tetracycline repressor (TetR) (Gossen and Bujard, 1992; Gossen et at., 
1995). The tetracycline uninduced (Tet-Off) and induced (Tet-On) gene expression systems 
(Clontech Inc.) take advantage ofthe high specificity and affinity ofTetR for its operator 
sequence (tetO) induced by tetracycline and its derivative antibiotic doxycycline. The 
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binding of TetR to tetO was also enhanced by fusing the herpes simplex vims (HSV) 
transactivation domain VP 16 to TetR generating the potent tT A protein (Gossen and Buj ard, 
1992). The Tet-Off system was initially developed with two components, the regulatory 
pTet-Offplasmid and the tetracycline response element (TRE) plasmid pTRE. The pTet-Off 
plasmid encodes the tTA fusion protein that is constitutively expressed upon stable 
transfection. The tTA protein binds doxycycline that is added to the culture media which 
prevents tTA from binding tetO sequences in the pTRE plasmid and initiating transcription. 
In order to tum on the desired gene expression inserted in the stably transfected pTRE 
plasmid, the culture medium containing doxycycline is removed and replaced with culture 
medium without doxycycline (Gossen and Bujard, 1992). Without the inhibitory 
doxycycline present, tTA binds the pTRE promoter which initiates the transcription of the 
desired gene. 
The Tet-On system was developed following the discovery of a mutant tTA protein. 
The pTet-On plasmid encodes a variant of the tTA protein, the reverse tetracycline 
transaction (rtTA) protein. The rtTA protein also binds doxycycline but when it is bound to 
doxycycline, rtTA behaves as an activator of transcription. In stably transfected cells grown 
in the absence of doxycycline, rtTA is unable to bind the pTRE promoter and therefore there 
is no gene expression from the pTRE plasmid (Figure 1.4). When doxycycline is present, 
it binds to rtTA and changes its conformation. rtTA then binds tetO in pTRE to activate 
transcription in a dose-dependent manner (Figure 1.4). Therefore, the control of gene 
expression can regulated by the addition of doxycycline. 
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A 
rtetR 
pTet-On regulatory plasmid 
rtTA 
Xrel3 -
pTRE2 response plasmid (OFF) 
B 
rtetR VP16 
pTet-On regulatory plasmid 
+ ++ 
.... ,...._._0---oxycyclin/ 
pTRE2 response plasmid (ON) 
Figure 1.4 Tet-On inducible gene expression system. (A) In the absence of doxycycline, 
the constitutively expressed rtTA (shown as a fusion oftTetR and VP16) is unable to bind 
the tetracycline responsive element (TRE) found in the promoter of pTRE2, therefore no 
Xrel3 is transcribed. (B) When bound to doxycycline, rtT A is able to bind the tetracycline 
responsive element (TRE) found in the promoter ofpTRE2, and initiateXrel3 transcription. 
(Adapted from Tet-On user manual). 
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The second regulatory element of the Tet-On system is the tetracycline response 
element (TRE) which is contained in the response plasmid pTRE2. The TRE consists of 
seven direct repeats of the 42 base pair (bp) tetO sequence immediately upstream of a 
minimal CMV promoter. The minimal CMV promoter does not contain any of the enhancer 
elements of the typical CMV promoter. Therefore, its activity is completely dependent on · 
the TRE. Therefore, in the presence of doxycycline, rtTA will bind the TRE to allow the 
assembly oftranscriptional machinery. Experimentally, the Tet-On system therefore requires 
a double-stable transfected cell line containing both pTet-On and a pTRE2 construct in 
which transcription can be regulated by doxycycline. 
1.5 Thesis Rationale 
Rel!NF-KB proteins can act as cellular pro-survival factors (Zong et al., 1999; De 
Smaele et al., 2001), while TGF-~ is a known suppressor of epithelial cell growth 
(Moustakas et al., 2001). It is therefore suggested that these two factors may play 
antagonistic roles in regulating cell proliferation. For example, TGF-~ 1 induces apoptosis 
in B cells by inhibiting NF-KB activity (Arsura et al., 1996) through the induction ofiKB-a 
expression (Azuma et al., 1999). Also, the up-regulation ofTGF-~ in antigen-presenting 
cells overexpressing thrombospondin causes down-regulation ofNF-KB (Masli eta!., 2002). 
Conversely, constitutively active NF-KB resulting from Ras- and Raf-transformation has 
been associated with TGF-~1 resistance (Arsura et al., 2000). In breast cancer cells, 
constitutively activated Rel!NF-KB modifies TGF -~ sensitivity (Sovak et al. , 1999). Further, 
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activation ofNF-KB by the latent membrane protein 1 ofthe Epstein-Barr virus leads to an 
inhibition ofTGF-P signaling (Prokova et al., 2002). 
Taken together, the accumulated data suggest that there may be a direct, mutually 
antagonistic relationship between the Rel!NF-KB and TGF-P signaling pathways that is 
commonly disrupted during tumorigenesis. For instance, many epithelial tumors are resistant 
to the growth suppressing effects ofTGF-P (ten Dijke et al., 2002). Also, NF-KB has been 
identified in many tumors to be constitutively active, and promote cell survival (Bours et al., 
1994; Luque and Gelinas, 1997). Although a reciprocal relationship has been suggested 
between the expression of NF-KB and SMAD proteins by others (Bitzer et al., 2000; 
Moustakas et al., 2001), it remains unclear whether there is a direct correlation between 
activation ofNF-KB and TGF-P resistance (Gurumurthy et al., 2001). 
The roles ofboth Rel!NF-KB and TGF -P superfamily members have been studied in 
Xenopus laevis embryos. Overexpression ofRelA in embryonic cells prevented mesoderm 
induction by activin (Kao and Lockwood, 1996). Recently, another Xenopus Rei member, 
Xrel3, was shown to prevent mesoderm induction by suppressing TGF-P-responsive 
embryonic patterning genes (Ford, Skhirtladze, and Kao; manuscript submitted). 
My hypothesis based on the results obtained from developing Xenopus embryos is 
that Xrel3 blocks the potential growth suppression effects ofTGF-P, allowing the cells to 
grow normally by interfering with the induction ofTGF -P-responsive genes. Therefore this 
thesis was designed to establish a tetracycline-inducible, Xre13-expressing human CaSki 
cervical carcinoma cell line for examining the effects of constitutive Rel!NF-KB on TGF-P 
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signaling and growth suppression. Foil owing the successful establishment of the CaSki-Tet-
On cell line, I determined the effects ofboth Rel!NF -KB induction and the addition ofTGF -~ 
on growth rates and morphology; the expression of appropriate markers using Western blot 
analysis; and used an apoptosis assay to correlate any changes in cell growth with potential 
changes in apoptosis. 
2.1 Cell Culture 
CHAPTER2 
MATERIALS AND METHODS 
28 
Human CaSki cervical carcinoma cells (ATCC) were grown in Dulbecco' s modified 
Eagles medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum (FCS), 100 
units/ml penicillin G, and 100 11g/ml streptomycin. Cells were maintained at 37°C with 5% 
C02 until reaching 70-90% confluence, washed with phosphate-buffered saline (PBS), and 
then were passaged using trypsin-ethylenediamine-tetraacetic acid (EDTA) (Invitrogen). 
Cells were counted using a hemocytometer (Fisher). 
2.2 Establishing Tet-Inducible Xre/3-Expressing CaSki Cells 
The TET-ON gene expression system (Clontech) involves the regulatory plasmid 
pTET -ON and the response plasmid pTRE2. To establish Tet-inducible Xre/3 cell lines, 
cells are first transfected with the pTET-ON vector, colonies are selected for neomycin 
resistance, screened for optimal transcriptional activation using a pTRE2-luciferase 
construct, and then stably transfected with pTRE2-Xrel3. Hygromycin-resistant clones must 
then be screened for Tet-dependent induction of Xre/3 to isolate the appropriate cell line. 
2.2.1 Establishing Stable CaSki-TET Clones 
Approximately 1 x 105 CaSki cells were seeded in 6 well plates and upon reaching 
70% confluency the cells were transfected with 1 11g pTET -ON using Lipofectamine reagent 
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(Invitrogen). Plasmid DNA was diluted in 100 Jll serum-free DMEM and combined with 
8 f.ll Lipofectamine reagent diluted in 100 f.ll setum-free DMEM for 45 min at room 
temperature to form DNA-liposome complexes. Following this incubation, 800 f.ll serum-
free DMEM were added to the complex mixture, which was then added to PBS-rinsed cells. 
Cells were incubated overnight with the complexes after which 1 ml ofDMEM + 20% FCS 
was added to each well followed by further incubation overnight. Then, the medium was 
aspirated, cells were washed with PBS, and fresh DMEM medium+ 10% FCS was added. 
Cells were allowed to grow for a further 24 hours and then were passaged 1: 10 into selective 
DMEM containing 400 IJ.g/ml G418 (Invitrogen) to isolate neomycin-resistant clones. The 
resulting clones were then subcultured in DMEM maintenance medium containing 200 
Jlg/ml G418 and screened for their induction of gene expression by doxycycline and a 
luciferase reporter construct, pTRE2-luc. 
2.2.2 Selecting Optimal CaSki-Tet Clone using Luciferase Assay 
To select the appropriate clone, it should have low background gene expression in 
the absence of doxycycline and high gene induction when doxycycline is present. Therefore, 
for obtaining the CaSki-Tet clone that highly expresses the desired gene product, each cell 
line was transiently transfected with pTRE2-luc and luciferase activity was measured with 
and without the addition of doxycycline. Cell extracts were prepared for the luciferase assay 
using reporter lysis buffer (Promega) as per instructions and relative luciferase activity was 
measured. Briefly, 400 Jll Reporter Lysis Buffer and were added to the pTRE2-luc 
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transfected cells. Cells were scraped from the dish and transferred to 1.5 ml tubes. Cell 
lysates were quick-frozen in liquid nitrogen, thawed in a 37°C water bath, chilled on ice for 
10 min and centrifuged for 10 min at 4°C. The supernatant was stored at -70°C until 
I 
luciferase activity was measured. 
Relative luciferase activity was determined by mixing 20 J.tl cell extract with 100 J.tl 
luciferase assay reagent (Promega) and measuring luminescence using a Monolight 2010 
luminometer (Analytical Luminescence Laboratory) for 10 sec following a 2 sec 
measurement delay. 
2.2.3 Tet-On Plasmid Construction 
pCS2-Xrel3 (Yang eta!., 1998) was digested with EcoRl andXhol to release the full-
length Xre13 eDNA, which was purified by 1% agarose gel electrophoresis and extracted 
using the QIAquick Gel Extraction kit (Qiagen). This eDNA fragment was ligated into the 
EcoRl and Xhol restriction sites of the tetracycline responsive plasmid, pTRE2, at room 
temperature for two hours with 1 U T4 DNA ligase (Invitrogen) [50 mM Tris-HCl (pH 7.6), 
10 mM MgC12, 1 mM adenosine triphosphate (ATP), 1 mM dithiothreitol (DTT), 5% 
polyethylene glycol, 3:1 insert:vector DNA] resulting in the plasmid pTRE-Xrel3. Also 
cloned was an Xre/3 eDNA containing a mutated nuclear localization signal (mutNLS) to 
give pTRE-mutNLS. Ligation products were incubated on ice with MAX Efficiency DH5 a 
competent cells in Terrific Broth (TB) (12 g/1 tryptone, 24 g/1 yeast extract, 0.4% glycerol, 
17 mM KH2P04, 72 mM K2HP04) for 30 min, heat-shocked at 42°C for 60 sec and chilled 
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immediately on ice for 2 min. Transformed cells were allowed to recover by adding 800 ~-tl 
TB broth to each sample and incubating at 37°C with shaking for 1 hour. Cells were applied 
to LB (Luria-Bertani) plates containing 100 ~-tg/ml ampicillin (Invitrogen) and incubated 
overnight at 37°C. Resulting colonies were selected and miniprep cultures in 2 ml TB broth 
containing 1 00 Jlglml ampicillin were prepared to identify desired plasmids by restriction 
digest analysis. Overnight cultures were prepared (200 ml TB broth containing 100 ~-tg/ml 
ampicillin) for each positive colony and plasmids were extracted using the Maxi-Prep kit 
(Qiagen) as instructed and DNA concentrations were determined using a spectrophotometer. 
Correct insertions were further confirmed at the 51 and 31 ends by direct DNA sequencing 
(DNA Sequencing Facility, Hospital for Sick Children, Toronto) for the plasmid constructs. 
2.2.4 Stable Transfection with pTRE2-constructs 
The tetracycline-responsive pTRE2-constructs were transfected into CaSki-Tet cells 
to produce stable Xre/3 and rtTA expressing cell lines. Briefly, approximately 2 x 105 
CaSki-Tet cells were seeded in 60 mm culture dishes (Coming) 24 hours prior to transfection 
in 1.6 ml DMEM. Effectene transfection reagent was used to co-transfect pTRE-Xre/3 
constructs and pTK-Hyg, a hygromycin selection vector. Briefly, both plasmids were diluted 
in buffer EC to a total volume of 150 ~-tl at 0.5 ~-tg!Jll concentration of both plasmids 
combined. Enhancer was added (8 1-t 1) and mixtures were incubated at room temperature for 
5 min before adding 25 ~-tl Effectene reagent to form transfection complexes. Cells were 
washed with PBS and 4 ml of complete DMEM were added. The complex mixtures were 
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diluted in 1 ml DMEM and added to the culture dishes. After 24 hours incubation, cells were 
passed 1:5 into 100 mm dishes and selected for hygromycin-resistance with 200 ).!g/ml 
hygromycin B (Clontech). Resulting clones were isolated using plastic cloning cylinders 
(Fisher) and seeded in 12-well culture dishes before passing to 100 mm dishes. Double-
transfectants were maintained in DMEM with 100 ).!g/ml hygromycin B to ensure that the 
cells retained the transfected plasmid. 
2.2.5 Genomic DNA Extraction 
To confirm the insertion of the appropriate pTRE2 construct, genomic DNA from 
CaSki, CaSki-Tet, and all double-transfected clones was isolated using the DNeasy Tissue 
Kit (Qiagen). In brief, approximately 5 x 106 cells were centrifuged for 5 min at 400 x g and 
resuspended in 200 J.!l PBS. To obtain RNA-free DNA, 4 J.!l ofRNase A (100 mg/ml) was 
added and the samples were incubated at room temperature for 2 min. To each sample, 20 
).!1 Proteinase K and 200 J.!llysis buffer were added and the tubes were mixed and incubated 
at 70°C for 10 min. After lysis, 200 ).!1 of 100% ethanol were added and the samples were 
added to DNeasy spin columns and centrifuged at 6000 x g for 1 min to bind the DNA. The 
spin columns were washed with 500 ).!1 ofbuffer AWl, centrifuged, washed with 500 ).!1 of 
buffer A W2, centrifuged, and then dried by further centrifugation at full speed for 3 min. 
DNA was eluted in 200 ).!1 elution buffer and centrifugation at 6000 x g for 1 min. 
Isolated genomic DNA was precipitated by adding 1110 volume of 3 M sodium 
acetate and 2.5 volumes of 100% ethanol. Tubes were placed in -70°C overnight. DNA was 
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pelleted at 12,000 x g for 25 min at room temperature and washed with 500 111 of 70% 
ethanol and centrifuged at 12,000 x g for 10 min. Supernatants were decanted and residual 
ethanol was removed by pipette. DNA pellets were air-dried for 5 min and resuspended in 
25 111 TE buffer (10 mM Tris, 1 mM EDTA) overnight at room temperature. DNA 
concentrations were determined from A260• 
2.2.6 Southern Blot Probe Preparation 
All stable Tet-On-Xrel3 cell lines were screened for the presence of pTRE2 
constructs using e 2P]-dCTP-labeled Xrel3. Full-length Xrel3 eDNA probes were labeled 
using Rediprime II random primer labeling kit (Amersham). Approximately 50 ng of probe 
was diluted in 445 111 TE buffer, boiled for 5 min to denature, and chilled for 5 min on ice. 
Denatured probe was added to the Rediprime reaction mixture, and incubated at 3 7°C for 15 
min with 5 111 ofe2P]-dCTP. The labeling reaction was stopped with 5 111 of0.2 M EDT A. 
Unincorporated radio labeled nucleotides were removed using Nuc-Trap probe 
purification columns (Stratagene). Columns were equilibrated with 70 1111 x STE buffer 
(100 mM NaCl, 20 mM Tris-HCl (pH 7.5), 10 mM EDTA] and then labeled probe was 
added to the top of the column and forced through the resin. To elute the probe, 70 111 1 x 
STE was added and pushed through the column into a collection tube. The incorporation of 
(32P]-dCTP was determined from 1 111 purified probe in 10 ml scintillation fluid. 
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2.2. 7 Southern Blot Analysis 
For Southern blot analysis, 8 )lg genomic DNA was digested with EcoRI and Xhol 
overnight at 37°e and resolved in a 0.8% agarose gel along with unlabeled Xrel3 eDNA as 
a control. Electrophoresis was approximately 20 hours at 30 V. DNA in the gel was 
depurinated for more efficient transfer oflarge DNA fragments in depurination solution (18 
ml 12 M Hel in 1 1 water) for 8-10 min with shaking. The gel was rinsed in deionized H20 
and soaked in denaturation buffer (0.5 M NaOH, 1.5 M Nael) for 30 min with gentle 
agitation. After H20 rinsing, the gel was soaked in neutralization buffer (0.5 M Tris, 1.5 M 
Nael) for 30 min and rinsed again. 
The Southern transfer apparatus was assembled according to standard methods. A 
piece of plexi-glass served as a platform that was laid across a Pyrex dish containing 20 x 
SSe (sodium saline citrate). The platfom1 was covered with 3 sheets ofWhatman paper 
soaked in 20 X sse to serve as a wick. The gel was then placed on the wick (well-side 
down) and surrounded with Parafilm. Hybond-XL nylon membrane (Amersham) was cut 
to size and placed carefully onto the gel, ensuring air bubbles were not trapped underneath. 
Three sheets ofWhatman paper soaked in 20 X sse were placed on the membrane. A 5 em 
stack of paper towels was placed on the top to create the capillary gradient. A glass plate 
and weight were added to the top and transfer proceeded overnight. The next day, the 
transfer apparatus was inverted and disassembled. The membrane was baked at 80°e for 2 
hours under vacuum to bind the DNA to the membrane. 
Hybridization of labeled probes was performed using the Rapid-Hyb buffer 
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(Amersham). Membranes were completely immersed in 65°e hybridization buffer and then 
incubated for 30 min with shaking in heat-sealed plastic bags for pre-hybridization. Xre13 
probes were denatured by boiling for 5 min and then chilled on ice. Approximately 200 000 
cpm of labeled probe was added to the bags and hybridization was performed for 1 hour at 
65°C. Following hybridization, membranes were washed as follows: 20 min in 2 X sse, 
0.1% SDS (sodium dodecyl sulphate) at room temperature; 15 min in 1 X sse, 0.1% SDS 
at 65°e; and 10 min in 0.1 X sse, 0.1% SDS at 65°e, until signal was localized using the 
Geiger counter. The washed membranes were wrapped in plastic wrap and exposed to film 
for autoradiography. 
2.2.8 Gene Expression Assay 
2.2.8.1 RNA Extraction 
Total cellular RNA was isolated from non-induced and doxycycline-induced eaSki 
cell lines using a RNeasy kit (Qiagen). Approximately 1 x 106 cells were seeded in 60 mm 
culture dishes 24 hours before doxycycline and/or TGF-~ 1 treatments. After 48 hours, cells 
were trypsinized and pelleted at 400 x g for 5 min before lysis with 500 J..Ll of supplied lysis 
buffer. Samples were homogenized by passing them through a 20-Gauge needle and 500 J..Ll 
of70% ethanol was added to each tube. All samples were centrifuged through the RNeasy 
spin columns to bind the RNA. After washing with the supplied wash buffers, total RNA 
was eluted from the column in 40 fll RNase-free water by centrifugation at 8000 x g for 1 
min. RNA concentrations were determined from the A260 of the samples. 
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2.2.8.2 Reverse Transcriptase-Polymerase Chain Reaction (RT -PCR) 
Clones were screened for the induction of Xrel3 RNA following treatment with 
doxycycline using RT-PCR analysis (Ding eta!., 2002). First strand complementary DNA 
(eDNA) was synthesized from 1.0 J.tglml total cellular RNA with 1.4 J.tl of0.2 J.tg/ml random 
primers (Invitrogen) in RNase-free water, heated to 70°C for 10 min, and placed on ice. 
Then 5x first strand buffer, 10 mM deoxynucleotide (dNTP) mix, 0.1 M DTT, and 1 Unit 
of Superscript II reverse transcriptase (Invitrogen) were added to begin eDNA synthesis. 
Samples were heated to 42°C for 50 min, 70°C for 15 min, and held at 4°C. A 320 bp 
fragment of Xrel3 template was then amplified from the eDNA using the following primer 
pair, Xrel3-Forward (5'-CCG CGG CCC CGA ATT CGA GC-3') and Xrel3-Reverse (5'-
AAC TGT GCGATC TGA ACC AA-3'). The ~-actin primer pair, Actin-Forward (5' ATC 
TGGCAC CAC ACC TTC TAC AAT GAGCTGCG-3') and Actin-Reverse (5'-ATG GCT 
GGG GTG TTG AAG GTC TC-3') was used to amplify a 142 bp product. Samples were 
amplified in 31 cycles of94°C for 40 sec, 55°C for 60 sec, and 72°C for 60 sec, followed by 
72°C for 7 min to ensure complete extension. Products were separated on 1% agarose gels, 
stained with ethidium bromide, and photographed with the Eagle Eye II still video system 
(Stratagene ). 
2.2.8.3 Protein Extraction 
Antibodies directed against PAI-l (Santa Cruz Biotechnology), VP16 (Clontech), 
SMAD2 (Transduction Laboratories) and phospho-SMAD2 (Upstate Biotechnologies), 
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SMAD7 (Santa Cruz Bioteclmology), P-actin (Sigma) , and p15 and p21 (Oncogene 
Research Products) were used for Western blot analysis to determine relative protein 
expressions. Cell proteins were extracted from 1 00 mm culture dishes as previously 
described (Yang et al., 1997). Cells were washed with ice-cold PBS and 1 ml of ice-cold 
lysis buffer (50mMTris-HClpH8.0, 150mMNaCl, 0.02% sodium azide, 1 %NP-40, 0.1% 
SDS, 0.5% sodium deoxycholate, 10 J.!g ofl 0 mg/ml phenylmethylsulfonyl fluoride (PMSF), 
and 5 J.!l of2 mg/ml aprotinin] was added to the cells which were then scraped into a 1.5 ml 
tube. Celllysates were chilled on ice for 30 minutes and centrifuged at 12,000 x g for 10 
minutes at 4°C. The supernatants were stored at -70°C. Protein concentrations were 
determined using the BioRad DC Lowry protein assay according to the manufacturer. 
2.2.8.4 Western Blot Analysis 
Protein extracts were mixed with equal amounts of2 x SDS gel loading buffer (200 
mM Tris, pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and boiled for 5 min. 
Denatured proteins were loaded onto the stacking gel [5% acrylamide, 125 mM Tris-HCl 
(pH 6.8), 0.1% SDS, 0.1% ammonium persulphate, 5 J.!l tetramethylethylenediamine 
(TEMED)] and separated in the resolving gel [10% acrylamide: 2.66% bis-acrylamide, 375 
mM Tris-HCI, pH 8.8, 0.1% SDS, 0.1% ammonium persulphate, 8 1-11 TEMED] for SDS-
polyacrylamide gel electrophoresis (PAGE) at 200 V in SDS-P AGE running buffer (25 mM 
Tris, 250 mM glycine) using a Protean II mini gel apparatus (BioRad). 
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2.3 Cell Proliferation Assay 
The CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) was 
used to determine the effects ofXrel3 expression on cell growth rates. This is a colorimetric 
method containing a MTS tetrazolium compound [3-( 4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-tetrazolium ], which is reduced by cells in the 
presence of an electron coupling reagent PES (phenazine ethosulfate) into a colored 
formazan product that remains soluble in DMEM. The reductiqn reaction involves 
dehydrogenase enzymes found in metabolically active cells and uses NADPH or NADH as 
the electron acceptor. Therefore, the amount offormazan produced, measured by the A490nm 
is directly proportional to the number of living cells in culture. 
CaSki, CaSki-Tet, CT-Xrel3, and CT -NLS cell growth rates were determined in four 
conditions: untreated; doxycyline-induced; TGF-P1-induced; and induction by both 
doxycycline and TGF-P 1. Approximately 5000 cells were seeded per well at 6 wells for 
each condition in 96-well plates. Doxycycline was added (1 1-!g/ml) at the time of seeding 
and cells were incubated at 37°C overnight. TGF-P 1 was added (2 ng/ml) to the appropriate 
wells and cells were incubated as indicated above. Medium was aspirated and replaced every 
24 hours. 
To determine the number of cells present in each condition, 20 !-!1 ofMTS solution 
was added to each well, the 96-well plate was returned to 37°C incubator for 2 hr and the 
absorbance at 490 nm of each well was recorded using a 96-well plate reader (Molecular 
Devices Inc.). 
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2.4 Hematoxylin and Eosin Staining 
The effects of Xrel3 expression and TGF-~1 treatment on cell morphology was 
determined using hematoxylin and eosin staining. Approximately 2 x 105 cells were seeded 
in 2-well cell culture chamber slides (Nunc) in DMEM or DMEM containing 1 !J.g/ml 
doxycycline. After 24 hours, medium was removed and replaced with DMEM, DMEM + 
1 J.lg/ml doxycycline, DMEM + 2 ng/ml TGF-P1, or DMEM +doxycycline and TGF-~1. 
After 48 hrs incubation, cells were washed with PBS and fixed with -20°C methanol for 5 
min. Methanol was aspirated and ceUs were left to air dry. The chambers were removed and 
the slides were immersed in PBS to wash and then stained in hematoxylin (Sigma) for 15 
seconds. Slides were immediately rinsed in running tap water for 1 min and then stained in 
eosin (Sigma) for 30 sees. Slides were processed in a dehydration series as follows: 1 min 
in 70% ethanol; 1 min in 95% ethanol; 1 min in 100% ethanol; and 3 minutes in xylene. 
Slides were mounted with Permount (Sigma) and coverslips were applied. 
2.5 Apoptosis Assay 
To determine whether the growth suppression due to TGF-~ treatments was due to 
apoptosis, the cells were stained with Annexin V-fluorescein isothiocyanate (FITC) and 
propidium iodide (PI) following the manufacturer's assay protocol (Pharmingen). Cells 
undergoing apoptosis are positive for Annexin V-FITC and negative for PI while cells at the 
end stage of apoptosis or already dead was stained positive for both Annexin V-FITC and 
PI. The percentage of stained cells were determined using flow cytomet1y and a fluorescence 
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activated cell sorter (F ACS) (Faculty of Medicine, Memorial University). 
Following 48 hrs of TGF-P treatment, each cell sample was collected by trypsin 
digestion along with all culture medium and PBS washes in a 50 ml tube. All attached and 
detached cells were pelleted by centrifugation at 400 x g for 5 min. Cells were resuspended 
in 1x binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaC12) at a 
concentration of 1 x 106 cells/ml. For F ACS analysis, 100 f..ll of cell suspension was mixed 
with 5 f..ll Annexin V-FITC, 10 f..ll PI and incubated for 15 min at room temperature in the 
dark. To each sample, 400 f..ll of 1 x binding buffer was added and samples were analyzed 
by the F ACS Analysis Facility, Faculty ofMedicine, Memorial University ofNewfoundland. 
CHAPTER3 
RESULTS 
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The objectives ofthese experiments were to: ( 1) construct the Tet-On Xrel3 induction 
system in CaSki cell line clones, (2) examine the effects ofXrel3 on cell morphology, (3) 
further determine whether Xre13 can modify TGF-P-induced growth inhibition, and finally, 
( 4) understand the molecular mechanisms involved. 
3.1 Xrel3 is a nuclear and constitutively active protein in CaSki cells 
To confirm potential interactions between Rel/NF-KB proteins and TGF-P signaling 
molecules, I chose to study a constitutively active Rel!NF-KB member, Xrel3. It had been 
shown in previous studies in Xenopus laevis that Xrel3 is found within the nucleus and is 
widely expressed (Yang eta/., 1998). To verify the behavior ofXrel3 protein in the human 
CaSki cervical cancer cell line, green fluorescent protein ( GFP)-tagged Xrel3 was transiently 
transfected into these cells. A cell permeable fluorescent DNA stain, 4',6'-diamidino-2-
phenylindole (DAPI) was used to confim1 the localization oftransfected proteins because it 
binds to DNA minor grooves within the nucleus. Empty GFP vectors produced only the 
green fluorescent protein that was diffusely expressed in both the cytoplasm and nuclei of 
transfected CaSki cells (Figure 3.1, A and B). GFP-Xrel3 on the other hand, was found in 
high abundance and almost exclusively in the nucleus (Figure 3.1, C and D). The NLS 
mutated form of Xrel3, altered by site-specific mutagenesis (mutNLS; kindly provided by 
Blue Lake) was also transfected into CaSki cells and used as a control. This mutNLS Xrel3 
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Figure 3.1 CaSki cellular localization of Xrel3 and its nuclear localization mutant, 
mutNLS. (A) Transiently expressed GFP is diffuse and present throughout the cell nuclei 
and cytoplasm when viewed under fluorescence. (C) GFP-tagged Xrel3 is targeted to the 
nucleus of CaSki cells and is not detected in the cytoplasm. (E) GFP-tagged mutNLS 
remains cytoplasmic with little to no expression within the nuclei. PanelsB, D, and F show 
the position of the corresponding cell nuclei using the DAPI stain for DNA. 
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protein (mutNLS) was only found in the cytoplasm ofCaSki cells when transiently expressed 
(Figure 3.1, E and F). This result suggests that the NLS motif is required for its nuclear 
localization and that mutNLS Xre13 can be used as a control for further experiments. 
3.2 Generation of Tet-inducible, Xrel3-expressing CaSki cells 
Initial attempts at creating stably-transfected, Xre13-expressing CaSki cells using the 
pcDNA3.1-Xre13 vector failed to produce viable, neomycin-resistant clones. It was 
hypothesized that the presence ofXre13 at a constitutively high level was toxic or prevented 
cell growth and that, if an inducible gene expression system was used, viable clones 
producing low Xrel3 levels could be established in which the expression ofXrel3 could then 
be induced at the appropriate time during an experiment. This conditional expression 
strategy is routinely used to examine the effects oflethal proteins or conditional oncogenes 
(Xie eta!. , 1999; Aurisicchoio eta/., 2001; Berkovich and Efrat, 2001). In addition, this 
approach reduces uncertainties of unknown cell changes occurring during clonal selection. 
For these reasons, the Tet-On system was chosen to stably transfect Xrel3 into CaSki cells 
in an inactive state and then to verify expression of Xrel3 experimentally following the 
addition of doxycycline (a tetracycline derivative) to the growth medium. 
3.2.1 Construction of stable pTet-On-transfected CaSki cervical cells 
The control plasmid p Tet-On contains the reverse tetracycline transactivation protein 
rtTA fused to the C-terminus of the herpes simplex virus VP16 activation domain (Gossen 
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and Bujard, 1992; Gossen et al., 1995). The rtTA fusion protein binds doxycycline and is 
necessary for subsequent initiation of transcription at the tetracycline response element 
within the Xrel3-containing plasmid. The transcription of rtTA is driven by the constitutive 
CMV promoter to give high levels of rtTA within the cells. After transfection, the resulting 
cell clones that exhibited neomycin-resistance were selected and subcultured in maintenance 
medium for determination of transcriptional activity. 
To test the integrity ofthe Tet-On system it was necessary to identify the clone that 
would have the highest transfection efficiency and have the highest ratio of induced to 
background expression. Therefore each clone was transiently transfected with the pTRE2-
luc construct and cultured in the presence or absence of doxycycline. The clone which has 
the highest induction ofluciferase activity, must also have a high transfection efficiency that 
is necessary to generate the final Xrel3-expressing clones. As shown in Figure 3 .2, ten 
clones tested had relatively low induction ofluciferase activity, in the range of 1 to 4 times 
background. In response to the addition of doxycycline, clone 7 had almost ·12 times greater 
luciferase activity than in the untreated medium. Therefore clone 7 has a high transfection 
efficiency and has the highest rate of doxycycline-induced luciferase activity. This clone 
was used for all further studies and subsequently identified as CaSki-Tet. 
CaSki-Tet was further analyzed by Western blot to confirm the presence of the 
reverse tetracycline transactivation domain rtTA using an anti-VP16 primary antibody. 
According to the manufacturer, the levels ofVP16 found in stably transfected cell lines may 
be below the sensitivity ofWestern analysis, but as shown in Figure 3.3, the levels ofrtTA 
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Figure 3.2 Selection of CaSki-Tet clones for doxycycline-responsiveness using a 
doxycycline-inducible luciferase assay. Untransfected CaSki and CaSki-Tet clones were 
transiently transfected with pTRE2-luc and cultured in the absence or presence of 1 !J.g/ml 
doxycycline for 48 hours. Luciferase activity was measured as relative light units (RLU). 
Only those clones with luciferase activity equivalent to or lower than untransfected CaSki 
background levels before doxycycline treatment are shown. (Two separate experiments). 
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Figure 3.3 Conformation of stable insertion of pTet-On in CaSki cells. Western blot 
analysis showing the presence ofrtTA fusion protein in the selected CaSki-Tet clone. The 
detection ofVP16 indicates successful insertion of the pTet-On vector in the CaSki and the 
successful transcription/translation of the 3 7 kDa rtTA fusion protein. According to the anti-
VP16 antibody manufacturer, cell artifacts (88 kDa) are detected by the anti-VP16 antibody 
and are not a result of the transfection. To confirm this, the same membrane was stripped 
and probed with anti-P-actin as a loading control whose expression was comparable in both 
CaSki and CaSki-Tet cells. 
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are detectable in CaSki-Tet cells but not in untransfected CaSki cells. The larger 
unidentified protein seen in both CaSki and CaSki-Tet extracts is found regardless of 
transfection. The manufacturer ofthe pTet-On system offers no explanation for the artifact 
therefore it is labeled "Cellular artifact". The observable difference in expression levels of 
this artifact between CaSki and CaSki-Tet cannot be accounted for at this time but was 
repeatable in three separate experiments. When the same membrane was probed with anti-P-
actin, comparable levels were found in both the CaSki and CaSki-Tet cells suggesting the 
amount of total protein loaded on the gel were the same (Figure 3.3). 
3.2.2 Construction of the tetracycline-responsive pTRE2-Xrel3 and pTRE2-mutNLS 
vectors 
Wild-type Xrel3 and mutNLS cDNAs were inserted into the EcoRI and Xhol sites of 
the doxycycline-response plasmid pTRE2, downstream of the tetracycline operator 
sequences (Figure 3.4). The insertion ofthese cDNAs was confirmed initially by restriction 
digest analysis and ultimately by direct sequencing from the 51 and 3 1 ligation sites (Figure 
3.4). 
3.2.3 Stable transfection of CaSki-Tet cells with pTRE2-Xrel3 and pTRE2-mutNLS 
CaSki-Tet cells were co-transfected with the pTRE2-Xre13 and pTRE2-mutNLS 
plasmids and pHyg (for antibiotic selection) at a ratio of20: 1 to favor selecting clones that 
incorporate co-transfected pTRE2-Xrel3 plasmids. Following transfection and selection, 
EcoRI Xrel3/mutNLS X hoi 
pTRE2 
EcoRI 1 
ATCGATTCG CCCAATGGCCGGTTTAAACGATCCCTACAT ... 
... TTTACAATGTACTGATCGCGAGCTCGGA :TCGAGGACTCTCG 
X hoi 
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Figure 3.4 Construction ofpTRE2-Xrel3 vectors. Complete copies (1.8 Kb) of wild type 
Xre/3 eDNA or the NLS-mutated Xre/3 eDNA were ligated into the EcoRI and Xhol 
restriction sites within the multiple cloning site ofthe pTRE2 plasmid. The resulting ligation 
products were sequenced at the 5' and 3' insertion sites to confirm proper orientation of the 
inserted cDNAs. 
49 
approximately 15 clones from each of the eDNA constructs were chosen and cultured in 
maintenance medium containing hygromycin until further selection by Southern blot, RT-
PCR, and Western blot analyses. 
The resulting clones were initially screened using Southern blot analysis to confirm 
the presence of the Xrel3 insert in the cell genomic DNA. To determine the presence of the 
Xrel3 insert, EcoRl and Xhol double digested genomic DNA was analyzed using [32P]-
labeled Xre13 probe. Xrel3 and mutNLS cDNAs were present in the successfully double-
transfected cell lines (CT-Xrel3 and CT-mutNLS) and was absent in CaSki and CaSki-Tet 
cell lines (Figure 3.5). 
3.2.4 Confirming the inducible expression of Xrel3 plasmids in CaSki cells 
In order to reveal the appropriate CT-Xrel3 and CT -mutNLS cell lines to use, further 
screening was necessary to prove the induction of Xre13 and mutNLS mRNA and protein. 
Clones that were positive for the insertion of p TRE-Xre13 and p TRE-mutNLS plasmids by 
Southern blot analysis were further screened for their ability to induce the expression of 
Xre13 and mutNLS mRNA using RT-PCR semiquantitative analysis and Western blot 
analysis to detect the translation of these mRNA molecules. 
3.2.4.1 Doxycycline induction of Xrel3 and mutNLS mRNA in CaSki-Tet cells 
To test the clones for the induction ofXrel3 and mutNLS mRNA, total cellular RNA 
was extracted from each clone before and after doxycycline treatments and used for R T-
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Figure 3.5 Genomic insertion of Xrel3 constructs in transfected CaSki-Tet clones. 
Cellular DNA was digested with EcoRl and Xhol to release the 1.8 Kb Xre/3 insert and 
probed with [32P]-labeled Xrel3 eDNA using Southern blot analysis. Digested pTRE-Xrel3 
was loaded as a control. 
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PCR. As a control, pTRE-Xrel3 plasmid was also amplified in identical conditions to detect 
the same 320 bp fragment. As expected, CaSki and CaSki-Tet did not express Xrel3 mRNA 
regardless of doxycycline treatment (Figure 3.6). CT-Xrel3 cells did not have detectable 
levels of Xrel3 mRNA in the absence of doxycycline. When doxycycline is added to the 
growth medium, there is aclearinductionofXrel3 mRNA. The same results are shown with 
CT -mutNLS cells; there are no detectable levels of mutNLS present in the absence of 
doxycycline, while there is a large increase in expression following 24 hours of doxycycline 
treatment. These combined results show both the tight regulation of transcriptional gene 
expression by the lack of detectable Xrel3 mRNA in the absence of doxycycline, and the 
specificity of induction by doxycycline. 
3.2.4.2 Translation of Xrel3 and mutNLS mRNA in CaSki-Tet cells 
In order to confirm the effectiveness of this cell model system it was necessary to 
further determine whether the transcribed mRNA was being translated to protein within these 
cell clones. Without an antibody raised against Xrel3, I decided to use an anti-serum raised 
against XrelA (Bearer, 1994) as a means of detecting Xrel3. Xrel3 and XrelA share 
homology (Yang eta/., 1998) and therefore it was predicted that anti-serum raised against 
XrelA could detect Xrel3 protein from lysates containing human proteins. Therefore, 
proteins were extracted from cell clones grown in DMEM with 2 J.lg/ml doxycycline and 
Xrel3 protein levels were accordingly probed using XrelA anti-serum. Figure 3. 7 shows the 
absence of detectable proteins with a molecular weight of 65 kDa in CaSki-Tet cells 
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Figure 3.6 Doxycycline-dependent transcription of Xrel3 and mutNLS in CaSki cells. 
RT-PCR analysis confirms the expression of Xre/3 and mutNLS mRNAs are only present 
when the double-transfected cells are grown in the presence of doxycycline. The levels of 
P-actin were also detected to control for the PCR reaction and as a loading control. Shown 
are the ethidium bromide stained 1.2 % agarose gels from both experiments. 
Untreated 
en 
-
...J 
~ M z Q) 
-
I :::::J 32 ~ E >< en I I 
n:s I- I-(.) (.) (.) 
90-
55-
2 IJg/ml Doxycycline 
en 
-
...J 
~ M z Q) 
-
I :::::J 32 ~ E >< en I I 
n:s I- I-
(.) (.) (.) 
+-- Xrel3 
(65 kDa) 
53 
Figure 3. 7 Doxycycline-dependent expression of Xrel3 protein in CT -Xrel3 cells and 
CT -mutNLS. Western blot analysis confirms the induction of the 65 k.Da Xrel3 protein in 
CT -Xrel3 cells only after the addition of doxycycline as detected using anti-XrelA serum. 
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regardless of the presence of doxycycline. However, upon the addition of doxycycline in 
CT -Xrel3 and CT -mutNLS cell cultures, a band was detected by the anti-XrelA serum at the 
corresponding molecular weight of approximately 65 k.Da for Xrel3 protein (Figure 3.7). 
The clones showing the greatest induction of Xrel3 and mutNLS at the protein level were 
chosen and subsequently termed CT-Xrel3 and CT -mutNLS cell lines, respectively. These 
results show the successful generation of human cervical cells with inducible expression of 
Xrel3, and its NLS mutant designed to be defective for nuclear translocation, which can now 
be further investigated to determine the effects ofthis gene and its functions on cell growth, 
morphology, and its potential roles in modifying TGF-P signaling. 
3.3 Xrel3 blocks cell morphological changes induced by TGF -~ 
The morphological appearance of in vitro cervical epithelial cells has been described 
(Stanley and Greenfield, 1992). Under ideal in vitro conditions, cultured cervical epithelial 
cells individually have a polygonal, flattened appearance; are slightly elongated; and contain 
frequent cytoplasmic protrusions and extensions when viewed under light microscopy 
(Stanley and Greenfield, 1992). Cultures of cervical epithelial cells typically grow in sheets 
of cells with a clear presence of mitotic figures, commonly around the edges of the cultures 
where the cells are spreading out to form the sheet-like epithelial structure (Stanley and 
Greenfield, 1992). These descriptions of cervical epithelial cells and cervical epithelial cell 
cultures, can be used to assess possible changes in the morphological appearance of CaSki, 
CaSki-Tet, CT-Xrel3, and CT -mutNLS cell lines grown in DMEM and in DMEM containing 
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doxycycline and/or TGF-~. 
The first experiments performed using this inducible CaSki cell system were to 
determine the effects of doxycycline and TGF -~on cell morphology in untransfected control 
CaSki cells. Untransfected CaSki cells were grown in DMEM with or without 1 J..lg/ml 
doxycycline, 2 ng/ml TGF-~, or both doxycycline and TGF-~. Figure 3.8 shows the effects 
of these culture conditions on cell morphology. Stained with hematoxylin and eosin, 
untreated CaSki cells have the predicted epithelial cell shape and appearance (Stanley and 
Greenfield, 1992) with long cytoplasmic protrusions and large numbers of mitotic figures. 
CaSki cells were seen as large sheets of epithelial cells growing closely together in the more 
confluent regions than in the outer edges of the culture. CaSki cells treated with doxycycline 
alone have a similar, epithelial appearance suggesting doxycycline does not alter the 
appearance ofCaSki cells within these specific parameters (Figure 3.8). 
TGF -~is an inhibitor of epithelial cell growth (Yue and Mulder, 2001 ). CaSki cells 
are epithelial in origin and have intact TGF-~ signaling pathways (Lee et al., 2001). I 
expected therefore, to detect signs of growth inhibition ofCaSki cells upon TGF-P treatment. 
As can be seen in Figure 3.8, CaSki cells show atypical growth inhibition in the presence of 
TGF-P, agreeing with previously published results (Lee et al., 2001). The cells grew in 
smaller regions without the characteristic cytoplasmic projections evident in the untreated 
or doxycycline-treated cells. The cell morphology was not as elongated or polygonal, 
resulting in a more rounded appearance and giving rise to the localized distribution of cells. 
There was a lower percentage of mitotic bodies present in these cultures as well (Figure 3.8 
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Untreated Doxycycline 
TGF-13 Doxycycline +TGF-13 
Figure 3.8 Untransfected CaSki cells grown in the absence or presence of doxycycline 
and/or TGF -~. Haematoxylon and eosin stained CaSki cells appeared to have characteristic 
epithelial growth patterns in DMEM and when treated with doxycycline. The addition of 
TGF-P largely suppressed the growth of CaSki cells to small colonies as depicted. This 
reduced gorwth pattern was also seen when TGF-P and doxycycline were added to the 
growth media. ( 400x magnification). 
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and Table 3.1 ), indicating cell division occurred at a slower rate. CaSki cells therefore were 
responsive, morphologically to TGF-P. The addition ofTGF-P and doxycycline together 
give the same result as TGF-P alone, with restricted cell distribution, fewer mitotic bodies, 
and fewer cells with normal flattened appearance characteristic of healthy epithelial cell 
growth (Figure 3.8). Therefore doxycycline did not interfere with the morphological effects 
ofTGF-P treatment on CaSki cells. 
The effect of the stable transfection of the pTet-On plasmid in CaSki-Tet cells was 
examined in cells cultured without doxycycline or TGF-P treatments. CaSki-Tet cells have 
the same epithelial appearance as CaSki cells when cultured in DMEM and when 
doxycycline is added (Figures 3.8 and 3.9). These results confirm that the insertion thepTet-
On plasmid which expresses the rtTA molecule, did not alter cellular morphology or growth 
characteristics in DMEM. Also as expected, no gross observable differences could be seen 
when doxycycline was added further suggesting that doxycycline at this concentration is 
unable to affect CaSki growth patterns and that the activated rtTA transcription factor did not 
alter the appearance ofCaSki-Tet cells under light microscopy (Figure 3.9). The growth of 
CaSki-Tet cells was also inhibited by TGF -P, even in the presence of doxycycline indicating 
that these cells maintain normal responsiveness to the growth factor. 
To determine the effects of Xrel3 expression on cell morphology, CT -Xrel3 cells 
were grown in DMEM in the absence or presence of doxycycline. Untreated CT -Xrel3 cells 
appeared morphologically similar to CaSki and CaSki-Tet cells, having the same polygonal 
shape, numerous cytoplasmic extensions (Figure 3.1 0), and similar numbers of mitotic 
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Table 3.1. Percentage of CaSki and CT-Xrel3 cells visibly undergoing 
mitosis in the presence of doxycycline and TGF -P. 
Treatment CaSki CT-Xrel3 
Untreated 4.06 ± 0.46 4.86 ± 0.98 
Doxycycline 4.87 ± 0.99 5.01 ± 0.55 
TGF-P 1.96 ± 0.76 1.29 ± 0.22 
Doxycycline + TGF-P 1.96 ± 0.34 3.96 ± 0.36 
Values indicate the percentage of mitotic figures counted ± standard deviation from three 
representative views from a single experiment. 
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Figure 3.9 CaSki-Tet cells grown in the absence or presence of doxycycline and/or 
TGF -(3. CaSki-Tet cells were stained with haematoxylon and eosin following 48 hrs of 
growth in the various culture conditions. Although stably transfected with the pTet-On 
plasmid, CaSki-Tet cells show characteristic growth patterns of epithelial cell cultures in 
DMEM or DMEM +doxycycline. Following treatments with TGF-(3, the vast majority of 
CaSki-Tet cells appear to be restricted to growth in small colonies, in the absence or 
presence of doxycycline. ( 400x magnification). 
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Untreated Doxycycline 
TGF-P Doxycycline +TGF-P 
Figure 3.10 CT -Xrel3 cells grown in the absence or presence of doxycycline and/or 
TGF-(}. CT-Xrel3 cells were stained with haematoxylon and eosin following 48 hrs of 
growth in the various culture conditions. CT-Xrel3 cells grown in DMEM and DMEM + 
doxycycline appeared flattened, elongated and contained periodic protrusions and extensions 
typical of epithelial cell morphology. In the presence ofTGF- p however, CT-Xrel3 cell 
growth was restricted to smaller colonies without the typical, sheet-like pattern seen in 
DMEM alone. Also noted, was the reduction of mitotic figures within these colonies. Xrel3 
expression by doxycycline treatment, prevented the growth pattern resulting from TGF- P 
alone, resulting in a typical epithelial cell morphology. ( 400x magnification). 
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figures as CaSki and CaSki-Tet control cells (Table 3.1). Importantly, the stable insertion 
ofthreeplasmids, pTet-On, pTRE-Xrel3, and pTK-Hygwithin CaSki cells did not noticeably 
alter the cellular morphology. CT-Xrel3 cells also grown in the presence of doxycycline 
appear morphologically like wild-type CaSki cells. Therefore, the expression of Xrel3 
protein induced by doxycycline, did not appear to alter the cell's appearance or growth. 
TGF -P treatments alone on CT-Xrel3 cells showed similar results to those of CaSki 
cells (Figures 3.8 and 3.10). There was a significant reduction in the number of cellular 
protrusions, and growth was contained within small clusters or colonies that lack the 
elongated shape oftypical cervical epithelial cells (Stanley and Greenfield, 1992). There was 
also a reduction in the number of mitotic figures present, indicating a reduction in cell 
division (Table 3.1). When CT-Xrel3 cells expressing Xrel3 were treated with TGF-p, the 
cellular morphology was more similar to that of the untreated cells as shown in the TGF-P-
treated untransfected CaSki cells (Figure 3.8 and 3.10). The cells had the appearance of 
untreated CaSki with mitotic levels comparable to untreated CaSki cells (Table 3.1 ). These 
results show the presence of Xrel3 is able to rescue typical cell growth patterns and 
morphology when treated simultaneously with TGF-P. 
The requirement of nuclear localization ofXrel3 was investigated in CT -mutNLS cell 
morphology under the various culture conditions. Stained CT -mutNLS cells appeared 
similar to untreated CaSki cells when cultured in DMEM alone, or when doxycycline was 
added to the medium (Figure 3.11 ). The cells have long cytoplasmic projections and there 
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Untreated Doxycycline 
TGF-13 Doxycycline +TGF-13 
Figure 3.11 CT-mutNLS cells grown in the absence or presence of doxycycline and/or 
TGF -J3. CT -mutNLS cells were stained with haematoxylon and eosin following 48 hrs of 
growth in the various culture conditions. The morphology ofCT -mutNLS cells was similar 
to the control CaSki cells when cultured in DMEM and DMEM +doxycycline. As with the 
other cell lines tested in this thesis, TGF-P was able to reduce the growth ofCT-mutNLS 
cells to smaller, tighter colonies with fewer mitotic figures and cytoplasmic projections. The 
presence of the NLS mutant Xrel3 did not prevent this growth suppression by TGF- P as 
shown in the last panel. ( 400x magnification). 
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are high numbers of cells undergoing mitosis. Upon the addition ofTGF-P however, there 
was the characteristic growth constraint found in TGF-P-treated CaSki and CaSki-Tet cell 
lines. The combination of doxycycline and TGF-~ treatments continued to cause the 
restriction of growth into smaller clusters with decreased cell numbers (Figure 3.11 ). These 
results indicate that, unlike the wild-type Xrel3, the NLS mutant is unable to prevent the 
growth inhibition by TGF -~. Therefore the observations suggest there is a direct interruption 
ofTGF-P signaling by Xrel3 which is dependent on its nuclear localization. 
3.4 Xrel3 blocks TGF -~-mediated cell growth inhibition 
The differential responses ofCaSki, CaSki-Tet, CT -Xrel3, and CT -mutNLS cell lines 
to TGF -~ treatments suggested that the different cell lines may have different growth 
characteristics in response to TGF-~. Therefore, the growth rates of each of the cell lines 
was determined using a colorimetric cell proliferation assay in the various culture conditions. 
Briefly, approximately 5000 cells were seeded in DMEM or DMEM containing 1 J.tg/ml 
doxycycline, for 24 hours before treatments with 2 ng/ml TGF -P. Absorbance was measured 
every 12 hours while the medium was changed every 24 hours with continuous doxycycline 
and TGF -~ treatments. 
CaSki control cells appeared to grow normally in DMEM + 10% FCS with a steady 
increase in absorbency between days 2 and 5.5, following an initial lag phase of 
approximately 24 hours (Figure 3.12). Consistent with the morphological data, the addition 
of doxycycline to the medium did not affect the growth curve. CaSki cells cultured in the 
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Figure 3.12 Effects of doxycycline and/or TGF-~ treatments on CaSki cell growth. 
Cells were cultured in the above conditions and the absorbance at 490 nm was recorded 
following incubation with the MTS substrate which directly correlated to the number of cells 
in the culture. (Error bars indicate standard deviation from six experiments.) 
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presence ofTGF-~, however, underwent significant cell growth inhibition with or without 
the presence of doxycycline in the culture media. After 5 days of incubation, the absorbance 
of the TGF -~-treated cells was approximately 55% of the untreated and doxycycline-treated 
cells. Thus, TGF -~ as expected, inhibits CaSki epithelial cell growth, which was unaffected 
by the addition of doxycycline. 
CaSki-Tet cells were also used as a control to ensure changes in growth in Xrel3 
expressing cells were not due to the stable transfection ofpTet-On plasmid or the presence 
of the rtTA protein. As shown in Figures 3.13, there were no apparent effects from either 
pTet-On or rtTA since the untreated CaSki-Tet cells grew comparably to untransfected CaSki 
cells (Figures 3.12 and 3.13). Doxycycline alone did not significantly change the growth 
curve, further indicating activated rtTA alone was not responsible for changes in cellular 
growth characteristics (Figure 3.13). The addition ofTGF-~ alone or in combination with 
doxycycline resulted in decreased cell numbers, confirming the morphological results seen 
in Section 3.3 and also confirming the stable insertion ofpTet-On was not contributing to 
changes in cellular appearance or growth patterns. 
The growth rates ofCT-Xre13 cell cultures within these same conditions were also 
investigated. When cultured in DMEM only, CT-Xrel3 cells grew normally as expected for 
untransfected cells (Figure 3.14). Therefore, the stable transfection ofpTRE-Xrel3 did not 
change normal growth rates. This is important, because any differences in this curve from 
that ofCaSki-Tet cells would be due to the random insertion ofthe pTRE-Xre13 plasmid into 
a critical element necessary for normal growth. After inducing the expression ofXrel3 with 
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Figure 3.13 Effects of doxycycline and/or TGF -~ treatments on CaSki-Tet cells. Cells 
were cultured in the above conditions and the absorbance at 490 run was recorded following 
incubation with the MTS substrate which directly correlates to the number of cells in the 
culture. (Error bars indicate standard deviation from six experiments.) 
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Figure 3.14 Effects of doxycycline and/or TGF-P treatments on CT-Xrel3 cells. Cells 
were cultured in the above conditions and the absorbance at 490 run was recorded following 
incubation with the MTS substrate which directly correlates to the number of cells in the 
culture. (Error bars indicate standard deviation from six experiments.) 
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doxycycline, the CT-Xrel3 cells continued to grow at an equal rate to that of uninduced cells 
(Figure 3.14). Thus, the expression ofXrel3 protein does not alter the normal control of cell 
proliferation in either a negative or positive way. When TGF-~ was added to the culture 
medium, uninduced CT-Xrel3 cells responded as did untransfected CaSki cells and growth 
rates were suppressed. After five days of culture in the presence ofTGF-~, the number of 
cells was approximately 50% of the cells in untreated conditions. Therefore, TGF-~ 
significantly decreases proliferation of CT-Xrel3 cells. 
I next examined the effects ofTGF-~ on the growth ofCT-Xrel3 cells when Xrel3 
expression was already induced by doxycycline. As seen in Figure 3 .14, the growth rate of 
Xrel3-induced, TGF-~-treated CT-Xrel3 cells did not appear to be growth inhibited 
throughout the five days of culture, and in fact, showed the same level of growth at the end 
of the experiment as the untreated cells in the absence and presence of doxycycline. This 
agrees with the morphological data of CT-Xrel3 seen in Figure 3.1 0. Therefore, expression 
ofXrel3 in CaSki cells appears to inhibit the growth suppression effects ofTGF-~ in CaSki 
cervical epithelial cells. 
The growth rates of CT -mutNLS cells were determined in the same manner as the 
previous cell lines. These cells exhibited normal growth rates in both untreated medium and 
also when doxycycline was present (Figure 3 .15) indicating that the stable transfection of the 
pTRE-mutNLS plasmid did not alter normal cell growth. TGF -~treatments on CT -mutNLS 
cells reduced cell numbers to approximately 55% of untreated cells following 5.5 days of 
treatment which is consistent with the results of TGF -~ treatments on the other cell 
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Figure 3.15 Effects of doxycycline and/or TGF-~ treatments on CT -mutNLS cells. Cells 
were cultured in the above conditions and the absorbance at 490 run was recorded following 
incubation with the MTS substrate which directly correlates to the number of cells in the 
culture. (Error bars indicate standard deviation from six experiments.) 
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types (Figure 3 .15). Also shown in Figure 3.15, the mutant NLS form of Xrel3 induced by 
doxycycline in CT -mutNLS cells was unable to prevent the growth inhibitory effects of 
TGF -~ as wild type Xre13 was able to do. Thus, the NLS region of the RHD appears 
necessary for this particular role of Xrel3. 
3.5 Xrel3 prevents transcription of TGF -P-induced target genes 
Xrel3 may suppress the responses to TGF-~ by interfering with either the TGF-~ 
signaling cascade, or at the level of transcription. I initially used CT-Xrel3 cells to 
investigate the levels of expression ofTGF-~-induced molecular targets in these cells when 
Xrel3 was expressed. One ofthe more common markers for positive TGF -~ signaling is type 
1 plasminogen activator inhibitor or PAI-l (Laiho et al., 1986; Lund et al., 1987; Keski-Oja 
et al., 1988; Sawdey et al., 1989; and Westernhausen et al. , 1991 ). In vivo, TGF-~ decreases 
cell growth by contributing to extracellular matrix (ECM) remodeling by elevating the 
production of fibronectin and procollagen and by increasing secretion of inhibitors of 
extracellular proteolytic enzymes such as PAI-l (Datta et a/., 2000). For these reasons, the 
protein levels ofP AI -1 were analyzed by Western blot to determine ifTGF -~ signaling was 
affected by the presence ofXre13. 
The levels of PAI-l in CaSki-Tet, CT-Xrel3, and CT-mutNLS cells treated or 
untreated with doxycycline and/or TGF-P are shown in Figure 3.16 and quantified in Figure 
3.17. In untreated and doxycycline-treated CaSki-Tet cells, very small levels of PAI- l 
expression were detected. The addition of TGF-~, alone or in combination with 
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Figure 3.16 Effects of Xrel3 expression and its nuclear localization on the expression 
of TGF-P-responsive genes. Total cellular protein was analyzed by Western blot to 
determine the expression levels ofTGF-P-responsive genes when Xrel3 and mutNLS were 
expressed. See text for description of results. (Representation of a minimum of three 
separate experiments for each protein detected.) 
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Figure 3.17 Densitometric analysis of PAI-l as compared to ~-actin control levels in 
CaSki cell lines. Levels ofP AI -1 protein expression detected by Western blot were plotted 
as a percentage of ~-actin control levels as recorded by densitometry. Error bars indicate 
standard deviation from triplicate experiments. 
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doxycycline, induced a significant increase in PAI-l protein expression in CaSki-Tet cells 
as expected. 
Untreated and doxycycline-treated CT-Xrel3 cells showed the same endogenous 
expression of PAI-l that was seen in CaSki-Tet cells when cultured under the same 
conditions (Figure 3.16). As expected, the level ofP AI-l increased significantly when the 
cells were treated with TGF-~ alone (Figure 3.16). However, when Xrel3 was expressed at 
the time of TGF -~ treatment, there was a significant reduction of induced PAI-l protein 
expression. This suggests that Xrel3 prevented successful transmission of the TGF-~ 
signaling cascade leading to PAI-l induction in CT-Xrel3 cells. 
CT-mutNLS cells also had very low PAI-l expression when cultured in DMEM or 
DMEM containing doxycycline (Figure 3.16). As with the previous two cell lines, TGF-~ 
was able to significantly induce the expression of PAI-l. When the NLS mutant ofXrel3 
was induced prior to TGF-~ treatment, the expression of PAI-l did increase significantly 
compared to the untreated and doxycycline-treated CT -mutNLS cells, as indicated in Figure 
3.16. 
3.6 Xrel3 does not inhibit SMAD2 phosphorylation 
TGF-~ signals through the SMAD family of proteins (Massague, 1998; Whitman, 
1998). In particular, SMAD2 phosphorylation has been implemented in PAI-l activation 
(Goumans et a!., 2002) along with SMAD3 (Datta et at., 2000). Therefore, tests of the 
phosphorylation ofSMAD2 could be used to determine if the block to TGF-~ signaling by 
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Xre13 was occurring upstream or downstream ofthis key event. Phosphorylated SMAD2 (p-
SMAD2) and unphosphorylated SMAD2 protein levels were detected in CaSki-Tet, CT-
Xrel3, andCT-mutNLS cells (Figure 3.16). CaSki-Tet cells grown inDMEM andDMEM 
containing doxycycline, exhibited high levels of SMAD2 with little detectable p-SMAD2 
protein expression. When treated with TGF-p, CaSki-Tet cells had significant induction of 
p-SMAD2 with subsequent reduction in unphosphorylated SMAD2, independent of the 
presence of doxycycline (Figure 3 .16). Untreated CT-Xre13 had low endogenous levels of 
p-SMAD2 and which remained unchanged after the induction of Xre13 expression with 
doxycycline. As expected, the levels ofp-SMAD2 increased upon treatment ofTGF-P in 
non-Xrel3 expressing cells. When Xrel3 was expressed in CT-Xrel3 cells at the time of 
TGF-P treatment, the levels ofp-SMAD2 were comparable to the TGF-P treated CaSki-Tet 
cells with no Xrel3 present. CT -mutNLS cells showed increased levels of p-SMAD2 protein 
in the presence ofTGF-p, regardless ofmutNLS expression induced by doxycycline (Figure 
3 .16). These results therefore indicate that Xrel3 did not affect SMAD2 phosphorylation in 
CaSki cells in response to TGF-p. 
3. 7 Xrel3 alters TGF -P induced expression of cell cycle regulators 
The formation, activation, and subsequent inactivation of cyclin-Cdk complexes 
allow progression through the cell cycle. At the G 1 checkpoint, the primary complexes 
involved are the cyclin D-Cdk4 and cyclin E-Cdk2 complexes (Hunter, 1993; Sherr, 1993). 
TGF-P induces cell cycle arrest in the Gl phase through several mechanisms (Figure 3.18), 
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Figure 3.18 Mechanisms of epithelial cell cycle inhibition by the activated TGF-~ 
receptor complex. TGF-P has been shown to inhibit c-Myc and cdc25A activity (cell cycle 
enhancers) and induce p 15 and p21 expression (cell cycle inhibitors) culminating in G 1 
arrest. 
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which alter the expression of G 1 cyclins, Cdk:s, and Cdk: inhibitors, preventing the G 1 to S 
phase transition (Geng and Weinberg, 1993; Sherr and Roberts, 1999). Two key 
mechanisms of TGF-P-induced cell cycle arrest are the induction of the cyclin E-Cdk2-
specific inhibitor p21 CIPIWAFI (Datto eta!., 1995a; Sewing eta!., 1997), and the induction of 
the Cdk:4-specific inhibitorp 15INK4n (Hannon and Beach, 1994; Ewen, 1996). Therefore, the 
expression levels of these proteins were investigated within this cell system. 
3. 7.1 Xrel3 inhibits induction of p21 CiptWAFI expression by TGF-P 
The induction of p21 cip/WAFl (p21) following TGF -P treatment aids in cell cycle arrest. 
p21 is involved in a complex composed of cyclin D, Cdk:4, and proliferating cell nuclear 
antigen (Xiong eta!., 1992). The first studies on p21 suggested that the transcription ofp21 
was controlled by p53 and p21 is an effector for the suppression of cell proliferation 
following DNA damage (Peter and Herskowitz, 1994; Waga et a!., 1994; Datto et a!., 
1995b). However, it has been shown that p21 is induced by TGF-P independently ofp53 
status and is a potent effector in TGF-P-induced growth inhibition. CaSki cells were also 
reported to have fully inducible, wild-type p21 expression (Funaoka eta!., 1996; Narayanan 
eta!., 1999). For these reasons, the induction of p21 was examined as a marker for TGF -P 
signaling within the CaSki cell model system and determine if Xre13 could prevent this 
specific mechanism of growth inhibition. 
CaSki-Tet, CT -Xre13, and CT -mutNLS cell lines showed relatively high endogenous 
levels ofp21 in the absence of doxycycline or TGF-P (Figures 3.16 and 3.19). The addition 
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Figure 3.19 Densitometric analysis of p21 Ciptwan as compared to J3-actin control levels 
in CaSki cell lines. Levels of p21 Ciptwan expression detected by Western blot were plotted 
as a percentage of P-actin control levels as recorded by densitometry. Error bars indicate 
standard deviation from triplicate experiments. 
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of doxycycline to the culture medium of CaSki-Tet cells, did not significantly alter the 
expression ofp21, which indicates doxycycline is unable to activate p21 expression. The 
expression of either wild-type Xrel3 or mutNLS also did not affect p21 expression levels in 
CT -Xrel3 or CT -mutNLS cells, respectively. As expected, the addition ofTGF-~ lead to an 
increase in p21 protein in CaSki-Tet, CT -Xrel3, and CT -mutNLS cell lines. In the CaSki-Tet 
control cells, the combined treatment of doxycycline and TGF-~ did not alter the induction 
ofp21 as the expression is similar to that found in TGF-~ treatments alone. Doxycycline-
induced CT -Xrel3 cells, but not CT -mutNLS however, show p21 levels that are similar to 
the endogenous levels in the presence of TGF-~ (Figures 3.16 and 3.19). Thus, the 
expression ofXrel3 inhibited p21 induction in CaSki cells. These results suggest that Xrel3 
was able to prevent cell growth inhibition induced by TGF-~ at least partly due to the 
prevention of p21 induction. 
3.7.2 Xrel3 does not affect TGF-~ induction ofp15INK4B expression 
TGF -~ is able to arrest cells in the G 1 phase also by the induction of p 15lNK4B (p 15) 
(Hannon and Beach, 1994; Reynisdottir et al., 1995; Reynisdottir and Massague, 1997). The 
mechanism of action ofp15 is different than p21 in that it inhibits Rb phosphorylation, 
maintaining it in a hypophosphorylated state via inhibition of the cdk4,6-cyclin D complex 
(Sherr and Roberts, 1999). Due to its alternate mode of growth inhibition, p 15 expression 
was also used as a marker for intact TGF -~ signaling. The p 15 expression levels are shown 
in Figure 3.16 and further quantified in Figure 3.20. 
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Figure 3.20 Densitometric analysis of p15INK48 as compared to J3-actin control levels 
determined by Western blot. Levels of p 15INK4B expression detected by Western blot were 
plotted as a percentage of P-actin control levels as recorded by densitometry. Error bars 
indicate standard deviation from triplicate experiments. 
80 
Untreated CaSki-Tet cells showed low, endogenous levels of p15 which did not 
change significantly when doxycycline was added alone. With the addition ofTGF-~, there 
was a significant induction of p 15 expression as expected. The combination of doxycycline 
and TGF-~, induced p15 expression to levels similar to TGF-~ treatments alone. These 
results indicate that doxycycline neither induces p15 itself, nor interferes with the induction 
ofp15 by TGF-P treatment. Untreated CT-Xrel3 cells express p15 at levels equivalent to 
untreated CaSki-Tet cells (Figures 3.16 and 3 .20). As expected, the addition of doxycycline 
alone did not affect p15 levels. CT-Xrel3 cells treated with TGF-~ show a significant 
increase in p15 protein, but, surprisingly, the presence ofXrel3 induced by doxycycline did 
not alter the induction ofp15 expression (Figures 3.16 and 3.20). CT-mutNLS cells have 
the same endogenous levels of p 15 in untreated and doxycycline-treated conditions and show 
equivalent induction of p 15 following TGF -~ treatments in the absence and presence of 
doxycycline. These results indicate that neither wild-type Xrel3 nor the mutated Xrel3 
proteins were able to prevent the induction ofp15 by TGF-p. 
3.8 TGF -P-induced CaSki growth inhibition is not due to apoptosis 
Various studies report various cell types respond to TGF -~ by growth arrest and 
eventually the cells enter an apoptotic pathway (Gurumurthy eta/., 2001; Bottinger and 
Bitzer, 2002; Gorelik and Flavell, 2002; Gressner eta!., 2002). Studies have also reported 
that TGF -~treatment ofHPV -16-containing cells induces apoptosis (Rorke and Jacobberger, 
1995). Therefore, it was hypothesized that the reduction in cell growth seen in Figures 3.12-
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3.15, may be due to increases in apoptosis and that Xrel3, a member ofthe anti-apoptotic 
proteins, may block this TGF-P response. To test this hypothesis, the percentage of cell 
death by apoptosis was measured for each cell line in the various culture conditions by flow 
cytometry using the annexin V -FITC staining kit. The percentages of apoptotic cells for 
each condition are shown in Table 3.2 as are the corresponding F ACS analysis (Figures 3.21-
3 .24). As indicated, TGF -P treatments did not lead to an increase in apoptosis in either 
CaSki, CaSki-Tet, CT-Xre13, or CT-mutNLS cell lines. Also noted was the induction of 
wild-type Xrel3 in CT -Xrel3 cells did not alter the percentage of apoptotic cells. These 
results suggest that in CaSki cervical cancer cells, TGF-P can inhibit growth independently 
of apoptosis, and more likely through the inhibition of cell cycle progression beyond the G 1 
phase. In addition, the presence of Xrel3 in CaSki cervical carcinoma cells did not affect 
apoptosis. 
Table 3.2. Percentage of apoptotic cells for each cell line 
following 48 hour treatments. 
Cell Line Untreated Doxycycline TGF-P Dox+TGF-P 
CaSki 6.31 ± 1.57 4.39 ± 1.23 4.92 ± 1.43 4.80± 1.80 
CaSki-Tet 7.51 ± 1.92 4.59 ± 1.80 7.71 ± 2.06 4.17 ± 1.18 
CT-Xrel3 5.48 ± 1.47 5.83 ± 1.84 7.45 ± 1.92 7.22 ± 2.23 
CT-mutNLS 4.35 ± 0.84 4.21 ± 1.52 4.94 ± 1.69 4.71 ± 1.55 
Values are the mean± standard deviation of six individual experiments. 
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Figure 3.21 Apoptosis ofCaSki cells following 48 hour treatments of either doxycycline 
and/or TGF-~. Apoptotic cells have high FITC and PI staining, and are shown in the upper 
right quadrant of each panel. Doxycycline and/or TGF-~ treatments did not significantly 
alter the percentage of apoptotic CaSki cells. 
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Figure 3.22 Apoptosis of CaSki-Tet cells fpllowing 48 hour treatments of either 
doxycycline and/or TGF -P. Apoptotic cells have high FITC and PI staining, and are shown 
in the upper right quadrant of each panel. Doxycycline and/or TGF-~ treatments did not 
significantly alter the percentage of apoptotic CaSki-Tet cells. 
. 
0 
0 
Untreated 
'.·, 
·. · . : :·. ·~·.··:: 
o• 
FITC 
TGF-(3 
.------------.--------. 
"' 0 
N 
0 
a:~ 
.. : .' . . ·., ~ . 
···:·:-:·· . 
. .. ·.· ·.·: ..· . 
104 
Doxycycline 
. · ' 
o• 
FITC 
Doxycycline+ TGF-13 
0 
~----------~--------~ 
M 
0 
N 0 
a:~ 
0 
" 0 
10. 104 
85 
Figure 3.23 Apoptosis of CT -Xrel3 cells following 48 hour treatments of either 
doxycycline and/or TGF -~. Apoptotic cells have high FITC and PI staining, and are shown 
in the upper right quadrant of each panel. Doxycycline-induced expression ofXre/3 and/or 
TGF-13 treatments did not significantly alter the percentage of apoptotic CT-Xrel3 cells. 
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Figure 3.24 Apoptosis of CT -mutNLS cells following 48 hour treatments of either 
doxycycline and/or TGF-~. Apoptotic cells have high FITC and PI staining, and are shown 
in the upper right quadrant of each panel. Doxycycline-induced expression of mutNLS 
and/or TGF -P treatments did not significantly alter the percentage of apoptotic CT -mutNLS 
cells. 
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4.1 Inducible expression system for Xrel3 was developed in CaSki cells 
In order to study possible interactions between the Rel!NF-KB and TGF-P families 
of signal transduction pathways, several factors had to be considered. First, due to the 
complexities and ubiquitous nature of both pathways, it was paramount to choose which 
particular member to study. Xrel3 of the ReliNF-KB family was chosen because its mRNA 
has been shown to be constitutively expressed in embryonic cells (Yang et al., 1998; Lake 
et al., 2001), and I have shown that Xrel3localizes to the nucleus when expressed in CaSki 
cells (Figure 3.1 ). Also, recent evidence i~:Idicates that during Xenopus mesode~ induction, 
Xrel3 is involved in mediating TGF-P superfamily members such as the Xenopus nodal-
related (Xnr) protein signaling and Xrel3 also interacts with the SMAD-associated FAST -1 
co-factor (K. R. Kao, personal communication). Xrel3 contains all Rel!NF-KB motifs 
including the RHD, a functional NLS domain, and a potential protein kinase A 
phosphorylation site (Yang eta/. , 1998). These preliminary observations suggested that 
Xrel3 and its NLS-mutated form (mutNLS) could be used to study potential interactions 
between Rel!NF-KB and TGF-P signaling mechanisms. 
The cell line chosen for these experiments was the human CaSki cervical cancer cell 
line. From previous studies, many tumor cell lines have been found to be resistant to TGF-P 
treatments, commonly due to mutations in either the TGF -Preceptors or mutations in SMAD 
signaling molecules, most notably SMAD4 (Akhurst and Derynck, 2001 ; Derynck et al. , 
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2001; W ak:efield and Roberts, 2002). However unlike most cancer cells, CaSki cells show 
marked sensitivity to TGF-~ treatments and have the ability to activate a number ofTGF-~­
responsive genes suggesting there is a complete, intact TGF -~signaling pathway (Lee et al., 
2001). For these reasons, CaSki cervical cancer cells were chosen for Xre13 expression 
studies and its effects on TGF-~ signaling pathway in my thesis. 
The Tet-On system is a proven method for controlling gene expression in many 
model systems, including primary and transformed cell lines, and more recently in transgenic 
mouse models (Gossen et al., 1995; Baronet al., 1997; Saez et al., 1997; Tremblay et al., 
1998; Wang et al., 1999; Ahmad et al., 2000; Baron andBujard, 2000; Zhu et al., 2002). A 
single transfected cell line can be induced to express the exogenous gene without the 
pleiotrophic effects that may occur by the isolation of separate cell lines for control and 
experimental cells. This model can therefore be used with a high degree of confidence for 
studying the interactions between Rel!NF -KB and TGF -~with all the benefits of an inducible 
gene expression system that allows for simple, straightforward interpretation of experimental 
results. I was able to construct an inducible CaSki cell line with both wild-type and NLS-
mutated forms ofXrel3 whose expressions were regulated by the addition of doxycycline to 
the cell culture medium (Figures 3.6 and 3.7). 
4.2 Xrel3 expression in CaSki cells 
Rel!NF-KB proteins are often activated in response to antiapoptotic, pro-survival 
signals (Luque and Gelinas, 1997; Caamafio and Hunter, 2002). This function ofRel!NF-KB 
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is due to its ability to regulate the expression of several antiapoptotic genes including 
TRAFl, TRAF2, c-IAPl, c-IAP2, IEX-lL Bcl-xt, and Bfl-1/Al (Wang et al., 1998; Wu et 
al., 1998; Grumontetal., 1999; Zongetal. , 1999; Khoshnan eta!., 2000). The antiapoptotic 
roles of Rel/NF-lCB where clearly demonstrated both in vitro and in vivo. For instance, 
embryonic fibroblasts lacking RelA activity are significantly more susceptible to tumor 
necrosis factor (TNF)-induced apoptosis while ReiA'- mice do not survive gestation due to 
TNF-induced apoptosis of liver cells (Beg et al., 1995; Alcamo et al., 2001). Normal 
embryonic development is rescued when TNF is also removed from the developing mice 
(Doi et al., 1999). 
When Xrel3 was expressed in CaSki cells, I saw no apparent changes in cell 
morphology or growth rates when cultured in DMEM or in the presence ofTGF-P (Figures 
3.10 and 3 .14). Further, the expression ofXrel3 did not significantly decrease the percentage 
of cells undergoing apoptosis (Figure 3.21 and Table 3.2). When cultured inDMEM + 10% 
FCS, CaSki cells are not exposed to apoptotic stimuli. Therefore, any anti-apoptotic effects 
due to Xrel3 expression would not normally be detected unless the cells were exposed to an 
apoptotic stimulus. 
Following a previous report which showed HPV-16-transformed cells treated with 
TGF -P had increased amounts of apoptosis (Rorke and J acobberger, 1995), I cultured all four 
CaSki cell lines in the presence ofTGF-P in order to test whether Xrel3 had any functional 
antiapoptotic, pro-survival mechanisms. Contrary to this report however, all four cell lines, 
including the untransfected, parental CaSki cell line, did not show significant increases in 
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apoptosis when treated with TGF-P alone (Figures 3.8-3.15 and Table 3.2). Without 
significant changes in apoptosis occurring in the presence of TGF-p, any possible 
antiapoptotic effects ofXrel3 expression could not be determined from these experiments. 
In order to fully address this possible function of Xrel3, CT-Xrel3 cells should be cultured 
in the presence of a potent activator of apoptosis such as TNF-cx before and after Xrel3 
induction. The preliminary information displayed in this thesis only indicates that Xrel3 
expression is not toxic to CaSki cells as suggested by the similar percentage of apoptotic 
cells in CT -Xre13 cultures containing doxycycline as those that where untreated (Table 3.2). 
4.3 CaSki growth suppression by TGF -P 
All cell lines studied in this thesis, CaSki, CaSki-Tet, CT-Xrel3, and CT-mutNLS 
were susceptible to the growth suppression effects of TGF-P (Figures 3.12 to 3.15). 
Recently, several cervical cancer cell lines were investigated for their responsiveness to 
TGF-P, and those that were unresponsive, were studied to determine if this was due to a 
particular mutation in the TGF -PIS MAD signaling process (Lee et al. , 2001 ). In this paper, 
the authors state that CaSki cells are moderately responsive to the presence of TGF-P 
showing only a mild reduction in the rate of cell growth when using the MTS assay. My 
results show that all four CaSki cell lines had significantly reduced cell growth following 
TGF-P treatment (Figure 3.12). While both studies used the same concentration ofTGF-P 
(2 ng/ml), the previous study only measured CaSki cell growth after three days of treatment 
but only presented data collected on another cervical cancer cell line, SiHa. Figures 3.12 to 
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3.15 show the response ofCaSki, CaSki-Tet, CT-Xrel3, and CT-mutNLS for 5.5 days of 
continuous TGF-~ treatment. It is clear from these figures that TGF-~-mediated growth 
suppression largely occurs in CaSki cells after the second day of treatment. Because they 
do not show their collected data for CaSki cell growth, it is my prediction that the authors 
of the previous paper simply did not measure cell growth long enough to see the full extent 
of the TGF-~ response. After five days of TGF-~ treatment, my cells did not reach 
confluency in the 96-well plate due to the growth suppression by TGF-~. Untreated or 
doxycycline-treated CaSki cells however, did reach confluency as indicated by the plateau 
in the growth curves ofthe four cell lines tested (Figures 3.12 to 3.15). CaSki cervical cells 
therefore, are fully responsive to TGF-~, most notable following 48 hours of treatment. It 
is now clear that CaSki cells have fully intact, fully functional TGF-~/SMAD signaling 
pathways. 
CaSki cervical cells are transformed by human papilloma virus (HPV) type 16. There 
are currently greater than 100 types ofHPV identified (Mfulger and Howley, 2002). HPV -16 
is considered a high risk HPV as is it highly associated with cervical cancer and malignancy. 
HPV -16 encodes two oncoproteins, E6 and E7 that are able to transform primary cervical 
cells into immortalized cells (Sun eta/., 1992; Tsutsumi eta/., 1992). It has been well 
established that E7 proteins from high risk HPV s form complexes with several cellular 
proteins including the retinoblastoma protein (pRb ), that is a key cell cycle regulator and 
tumor suppressor gene (Alani and Mfulger, 1998). 
HPV E7 was recently reported to block TGF -~ signaling and inhibition of cell 
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proliferation by directly inhibiting SMAD-DNA binding in HepG2 and MvlLu cell lines 
(Lee et al., 2002). From the results of this paper, one would expect that CaSki cells should 
not be sensitive to TGF -~ due to the presence ofE7. In our studies and those of others (Lee 
et al., 2001), CaSki cells were sensitive to TGF-~. It is possible that due to mutations, 
CaSki cells do not express E7 at adequate levels to alter SMAD-DNA binding. To date, 
there has been no reported evidence demonstrating E7 protein levels in CaSki celllysates 
that would confirm or refute this possibility. A more likely explanation for these 
contradictions in TGF-~ sensitivity and E7 expression is the cellular context in which these 
experiments were conducted. Specifically, these transfection experiments were conducted 
usingnon-cervical cells overexpressing E7, and SMADs 2,3,and 4 proteins. The authors 
chose to use HepG2 and MvlLu cells, a human liver cell line and a mink lung epithelial cell 
line as their in vitro model ofHPV infection and cervical carcinoma (Lee et al., 2002). The 
reasons for choosing these cell lines were never stated within the paper. There is also no 
comment on the endogenous SMAD protein levels prior to the overexpression of exogenous 
proteins. It is likely that the overexpression of individual SMADs alters the cellular response 
to TGF-~ treatments. The authors conclude that their results are applicable to cervical 
carcinoma in that the expression ofE7 is responsible for the insensitivity to TGF-~ seen in 
many cervical tumors (Lee et al., 2002). Contrary to this conclusion, Rorke et al. (2000) 
reported that cell cycle arrest of human HPV-16-immortalized cells by TGF-~ was also 
correlated with a decrease in E6/E7 mRNA and an increase in p21 expression. My evidence 
leads me to conjecture that the TGF-~ growth inhibition ofCaSki cells, presented both in this 
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thesis and by others (Lee eta!., 2001), is a more accurate description of cervical cancer. The 
roles ofHPV proteins in the TGF-P signaling mechanism remain unclear. It is therefore 
obvious that more research is required to fully understand the effects ofHPV infection on 
TGF -PIS MAD signaling. 
4.4 Cell cycle arrest by TGF -P is inhibited by Xrel3 in CaSki cells 
Epithelial cell proliferation can be regulated by TGF-P. Cells respond to TGF-P 
ligand binding by arresting the cell in the Gl phase of the cell cycle. This is accomplished 
by at least four TGF -P-specific responses including the inhibition of c-myc, the induction 
ofp15INK4B, the inductionofp21 ciP/WAFI, and the inhibition ofcdc25A(ten Dijkeet a!., 2002). 
These mechanisms (Figure 3 .18) are ligand-specific and tissue-specific responses that are 
unique to each cell condition and differentiation stage. My present study examined the 
effects of Xrel3 on only two of these pathways, the p21 and p 15 tumor suppressor protein 
activation pathways. The induction of both p 15 and p21 occurs via SMAD-dependent 
signaling (ten Dijke et al., 2002). The mechanism of c-Myc and cdc25A inhibition by TGF-
P is still unclear however, it does involve an adapter protein, the Myc-interacting zinc-fmger 
protein 1 (Miz-1) that negatively regulates TGF-P signaling (Secane et al., 2001; Staller et 
al., 2000) which may not involve the SMAD signaling molecules. 
As was shown in Figure 3 .18, p 15 is a cdk4-specific inhibitor and therefore functions 
early in the G 1 phase ofthe cell cycle. The cdk2-specific inhibitor p21 functions later in the 
G 1 phase and into the S phase. These temporal differences in activation of cdk inhibitors 
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may account for the variations in p 15 and p21 observed in my studies in response to Xrel3 
expression. As a first possibility, my data suggested that Xrel3 was able to prevent p21 
induction and block growth inhibition, whereas it had no effect on p 15 (Figure 3 .16). This 
could suggest that Xrel3 may act only on transfected CaSki cells during later phases of the 
Gl/S transition. Secondly, Xrel3 may alternatively be acting on a specific SMAD protein 
that is used only in the induction of p21 but not of p 15. Since various combinations of 
SMAD proteins as dimers are used to carry signals to the nucleus, it is possible that p21 
induction and p 15 induction have distinct SMAD dimers and that Xrel3 is only able to 
interact with the p21-specific dimer (Figure 4.1 ). A third possible explanation is that Xrel3 
blocks the binding of an obligate transcription factor to the specific SMAD dimer. As 
depicted in Figure 1.3, the binding of SMAD proteins requires an auxiliary protein (for 
example, Fast-1) to enhance DNA binding and transcriptional activation. The up regulation 
of p 15 and p21 cyclin-dependent kinase inhibitors by TGF -P leads to the specific inhibition 
of cyclinD-CDK4/6 and cyclinE-CDK2-dependent phosphorylation of retinoblastoma 
protein (pRb ), respectfully (ten Dijke et al., 2002). The upregulation of both of these 
inhibitors (Figure 4.1) occurs via Sp1 binding sites (Datto et al. , 1995; Li et al., 1995). It is 
therefore conceivable that Xrel3 either competes for SMAD binding with Spl or Fast-1 
transcriptional regulators or is indirectly responsible for blocking the formation of these 
complexes. 
The results of this project show that Xrel3 is able to inhibit the TGF-P-mediated 
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Figure 4.1 Potential actions of Xrel3 in preventing growth arrest by TGF -13 and its 
effects the expression of TGF- J3 markers. Based on the results of this thesis, Xrel3 is 
likely functioning later in G 1-S phase transition where it is able to interfere with the 
induction of p21, but not p 15. These specific interactions may involve SMAD3/SMAD4 
complexes binding to DNA directly, or may require other co-transcriptional suppressors or 
activators such as FAST -1. 
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induction of p21 but not of p 15. From the growth curves of CT -Xrel3 and control cell lines, 
cell proliferation is halted following TGF-~ treatment such that after five days of treatment, 
less than 50% of untreated cells are present. However, when Xrel3 was present, cell 
proliferation rates are restored to that of the untreated cell lines in the presence ofTGF-p. 
Due to the quick recovery of cell growth, it was predicted that Xrel3 was able to prevent all 
of the TGF -P-dependent mechanisms of cell cycle arrest. However, my results indicate that 
p15INK4B induction is unaffected by the presence ofXrel3. Therefore, Xrel3 appears to act 
in a specific manner. The current data simplifies the possible mechanism of Xrel3 
interaction to that shown in Figure 4.1. Much more research is required to further 
characterize the specific interactions between TGF-P signaling molecules and Rel!NF-KB 
and to fully understand how these antagonistic pathways are balanced within normal and 
cancer cells using conditions of abnormal expression. Therefore this cell model system will 
be useful for conducting such experiments as outlined in the following sections. 
4.5 Future experiments with inducible Xrel3 CaSki cell model 
4.5.1 Does Xre13 affect other TGF-~-inducible cell cycle regulators? 
Western blot analysis should be utilized to further investigate the interactions 
between Xrel3 and TGF-~/SMAD signaling. Based on the results shown in this thesis, it 
seems that Xrel3 is not able to affect all cell cycle regulators downstream of TGF-P 
signaling. It would therefore be advantageous to determine if Xrel3 can block the actions 
of TGF-~ signaling on other known TGF-~ responsive genes such as c-Myc, p27, and 
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cdc25A levels. 
The cell cycle regulator c-Myc normally functions to prevent p15 activity and 
therefore allows regular cell cycle progression (Gartel and Shchors, 2003). Upon TGF-P 
treatment, c-Myc levels decrease, resulting in p 15 activation which then contributes to 
arresting the cell in G 1 phase. It could be hypothesized that Xrel3 is unable to affect c-Myc 
based on this function. It has been shown by others that c-Myc also functions to inhibit 
TGF -P-induced p21 expression (Seoane et al., 2002). My results demonstrate that Xrel3 can 
interfere with p21, and it may also interfere with c-Myc-specific inhibition of p21 activity. 
Therefore it warrants further study into the effects ofXrel3 expression on c-Myc protein in 
the presence ofTGF-P. 
The cdk tyrosine phosphatase enzyme cdc25A, normally controls cell cycle 
regulation by maintaining p27 in an unphosphorylated state (Nagahara et al., 1999). When 
TGF-P is present, the activated receptor complex inhibits cdc25A function possibly through 
the SMAD proteins. When this occurs, p27 is activated and is recruited to cyclin E-cdk2 
complexes causing a reduction in cell cycle progression. It would be important to determine 
if Xrel3 is able to prevent the inhibition of cdc25A activity and in addition, determine if 
Xrel3 can block the formation ofp27/cyclin E/cdk2 complexes. These experiments would 
be beneficial for confirming this novel function ofRel!NF-KB proteins. 
4.5.2 Does Xrel3 affect other SMAD signaling molecules? 
The abilities ofTGF-P to control cellular functions and gene expression are largely 
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dependent on the SMAD family of proteins (ten Dijke et al., 2002). The results displayed 
here show that Xrel3 cannot prevent SMAD2 phosphorylation. It is now compelling to 
further investigate the status of phosphorylated SMAD2 in these cells to determine if 
SMAD2 is still active. This experiment could be conducted using immunocytochemistry to 
analyze the cellular localization of phosphorylated SMAD2. 
The expression levels ofSMAD3, phosphorylated SMAD3, and SMAD4 should be 
analyzed to determine if activation ofthese SMAD proteins are affected by Xrel3. As noted, 
SMAD3 is another member of the R-SMADs that can be activated following TGF -P ligand-
binding while SMAD4 is the only known co-SMAD in human cells (ten Dijke et al., 2002). 
For a complete understanding of the actions ofXrel3 on TGF-P signaling in CaSki cells, it 
would be necessary to consider the expression of these other SMAD signal transducers. For 
instance, TGF -P activation of PAI-l transcription likely involves a SMAD3/SMAD4 dimer 
(Song eta/., 1998) while the activation of p21 involves SMAD3/SMAD4 in concert with the 
Sp 1 transcription factor (Pardali eta/., 2000). In astrocytes, the induction of p 15 by TGF -P 
is dependent on SMAD3 signaling and may also be responsible for its induction in cervical 
epithelial cells (Rich eta/., 1999). Cellular localization and Western blot experiments would 
therefore be beneficial for examining the specific SMAD activation occurring in these cell 
lines. 
SMAD7 levels could not be detected in these CaSki cell lines by Western blot. 
SMAD7 is an inhibitory SMAD that is involved in a negative-feedback loop that silences the 
TGF-P signal transduction once the stimulus is removed (Moustakas et al., 2001). It is 
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possible that CaSki cells simply do not express SMAD7 due to mutations within its gene 
sequence or that Western blot analysis is not sensitive enough to detect its expression. The 
other known inhibitory SMAD, SMAD6, may also be key within these cell lines due to the 
inability to detect SMAD7 expression. Assessing the expression levels of SMAD7 and 
SMAD6, and also their translocation events following Xrel3 expression, are other key 
experiments that would help determine the specific function that Xrel3 is performing in these 
cell lines and possibly in tumor specimens. 
Recently, growing evidence ofSMAD-independent transduction ofTGF-P signals 
in various cell and tissue types has emerged in the literature. For instance, TGF -P 1 decreases 
the secretion of glycoproteins in adrenocortical cells by activating c-Jun and MEKK 
signaling (Lafont et al., 2002); activates the p38 MAPK pathway in mouse mammary 
epithelial cells (Yu eta!., 2002); and simultaneously activates JNK activity in MvlLu cells 
apart from SMAD molecules (Engel et al., 1999). In addition, another TGF-P superfamily 
member BMP-2 can induce apoptosis in human osteoblasts via the protein kinase C pathway 
(Hay et al., 2001 ). Therefore, it is conceivable that Xrel3 may also be influencing a SMAD-
independent signaling mechanism within transfected CaSki cells since SMAD2 
phosphorylation in Xrel3-expressing cells and the parental CaSki cells . This point 
emphasizes the need to further characterize precise interactions between Rel!NF-KB and 
TGF-P family members that may be occurring in these cells and many other, different cell 
lines and tissue specimens. 
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4.6 Future Directions 
The studies described in this thesis were initiated based on observations that many 
tumors have constitutively active Rel!NF-KB and insensitivity to TGF-P treatments. The 
results shown in this cell model system now suggests that these observations may be more 
than just correlative. Instead, my findings provide preliminary evidence that there can be a 
direct association between the Rel!NF-KB and TGF-P pathways and more importantly, they 
provide a precedent for further studies of this relationship. To this extent, a number of 
studies can be proposed. Firstly, to further characterize the exact mode of interaction 
between Xrel3 within this CaSki cervical cell system on blocking TGF -P signaling, recent 
technologies including pathway-specific gene array analysis (GEArray, SuperArray 
Bioscience Corporation) can be used to examine changes in the expression of genes closely 
related to Rel!NF-KB and TGF-P signaling pathways. Secondly, various other cancer cell 
lines that are known to have either constitutive Rel!NF-KB activity or TGF-P insensitivity 
can be examined. It is my hypothesis that a correlation exists between these two events in 
various available cell lines. Thirdly, it will be interesting to survey various tumor specimens 
from clinical samples to characterize the status of Rel!NF-KB and TGF-P pathways and 
determine if abnormally active Rel!NF-KB is responsible for TGF-P insensitivity in tumors 
that develop resistance to its growth inhibitory effects. 
To investigate how Xrel3 is able to prevent normal CaSki cell growth inhibition by 
TGF-P treatment, pathway-specific gene array kits could be used (SuperArray Bioscience 
Corporation). RNA from untreated and doxycycline-induced CT-Xrel3 cells grown in the 
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presence or absence of TGF -~ is extracted and hybridized to membranes blotted with 96 
cDNAs of genes closely related to either the Rel/NF-KB or the TGF-~/SMAD signaling 
pathways. Following autoradiography, changes in gene expression are quantified by 
densitometry to highlight genes that are either significantly down-regulated or up-regulated 
in the presence ofXrel3 protein. The identification of those genes significantly affected by 
the presence ofXrel3 will lead to a better understanding ofthe specific mechanisms of action 
that Xrel3 has on modifying TGF -~ signaling. These key findings may eventually lead to 
possible areas oftherapeutic intervention in various tumors that no longer respond to TGF -~ 
treatments. 
The second major research focus area arising from this thesis is to survey the status 
ofReliNF-KB and TGF-~-responsive cancer cell lines. Each cell type could be first assayed 
for constitutive Rel activity using immunocytochemistry. Cells can be probed with primary 
antibodies specific for various Rel family members, then incubated with the appropriate 
fluorescence-labeled secondary antibody to visualize the location of the Rel protein in 
normal, non-stimulated culture conditions. Cell lines showing nuclear localization of Rel 
proteins in normal medium can be identified as having constitutively active Rel/NF-KB. The 
same cell lines could also be cultured with TGF-~ to see if there is a correlation between 
constitutive Rel/NF -KB activity and insensitivity to TGF -~. The results ofthis thesis predict 
that such a correlation is highly possible. There have been no studies to date however, which 
can prove or disprove such an hypothesis. Cancer cell lines that prove to be insensitive to 
TGF -~ and do not show growth inhibition can be treated with various known inhibitors of 
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Rel activity. It is my prediction that these cells will subsequently respond to the TGF-P 
treatments once Rei activity'has been blocked. If this prediction holds, then more clinical 
studies could be initiated using common Rei inhibitors such as the non-steroidal anti-
inflammatory drugs, that could be used in combination with TGF -P to enhance the 
therapeutic benefits of cancer treatments involving tumors of epithelial origin. 
The third new focus evolving from this present study is to investigate these 
interactions in pathological conditions. Various tumor sections and adjacent normal tissues 
from various cervical cancer patients can be analyzed by immunohistochemistry, differential 
gene array analysis, and Western blotting to determine whether Rel!NF-KB activity blocks 
TGF-P mediated growth inhibition in clinical specimens. Biopsies taken from pre- and post-
chemotherapy can be assessed for constitutive Rei activity and correlated to the tumor 
responsiveness to TGF-p. Again, our present model predicts that Rei activity is blocking 
normal responses to TGF-p, not only in vitro but also in vivo. 
In summary, my preliminary findings suggest that Rel!NF-KB regulates TGF-P 
signaling in human cervical cancer cells and provide the basis for further molecular and 
biological studies involving these pathways. 
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